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A B S T R A C T
Background
Despite the availability of effective drug therapies that reduce low-density lipoprotein (LDL)-cholesterol (LDL-C), cardiovascular
disease (CVD) remains an important cause of mortality and morbidity. Therefore, additional LDL-C reduction may be warranted,
especially for patients who are unresponsive to, or unable to take, existing LDL-C-reducing therapies. By inhibiting the proprotein
convertase subtilisin/kexin type 9 (PCSK9) enzyme, monoclonal antibodies (PCSK9 inhibitors) may further reduce LDL-C, potentially
reducing CVD risk as well.
Objectives
Primary
To quantify short-term (24 weeks), medium-term (one year), and long-term (five years) effects of PCSK9 inhibitors on lipid parameters
and on the incidence of CVD.
Secondary
To quantify the safety of PCSK9 inhibitors, with specific focus on the incidence of type 2 diabetes, cognitive function, and cancer.
Additionally, to determine if specific patient subgroups were more or less likely to benefit from the use of PCSK9 inhibitors.
Search methods
We identified studies by systematically searching theCochraneCentral Register of ControlledTrials (CENTRAL),MEDLINE, Embase,
andWeb of Science.We also searchedClinicaltrials.gov and the International Clinical Trials Registry Platform and screened the reference
lists of included studies. We identified the studies included in this review through electronic literature searches conducted up to May
2016, and added three large trials published in March 2017.
Selection criteria
All parallel-group and factorial randomised controlled trials (RCTs) with a follow-up time of at least 24 weeks were eligible.
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Data collection and analysis
Two review authors independently reviewed and extracted data. When data were available, we calculated pooled effect estimates.
Main results
We included 20 studies with data on 67,237 participants (median age 61 years; range 52 to 64 years). Twelve trials randomised
participants to alirocumab, three trials to bococizumab, one to RG7652, and four to evolocumab. Owing to the small number of trials
using agents other than alirocumab, we did not differentiate between types of PCSK9 inhibitors used. We compared PCSK9 inhibitors
with placebo (thirteen RCTs), ezetimibe (two RCTs) or ezetimibe and statins (five RCTs).
Compared with placebo, PCSK9 inhibitors decreased LDL-C by 53.86% (95% confidence interval (CI) 58.64 to 49.08; eight studies;
4782 participants; GRADE: moderate) at 24 weeks; compared with ezetimibe, PCSK9 inhibitors decreased LDL-C by 30.20% (95%
CI 34.18 to 26.23; two studies; 823 participants; GRADE: moderate), and compared with ezetimibe and statins, PCSK9 inhibitors
decreased LDL-C by 39.20% (95% CI 56.15 to 22.26; five studies; 5376 participants; GRADE: moderate).
Compared with placebo, PCSK9 inhibitors decreased the risk of CVD events, with a risk difference (RD) of 0.91% (odds ratio (OR)
of 0.86, 95% CI 0.80 to 0.92; eight studies; 59,294 participants; GRADE: moderate). Compared with ezetimibe and statins, PCSK9
inhibitors appeared to have a stronger protective effect on CVD risk, although with considerable uncertainty (RD 1.06%, OR 0.45,
95% CI 0.27 to 0.75; three studies; 4770 participants; GRADE: very low). No data were available for the ezetimibe only comparison.
Compared with placebo, PCSK9 probably had little or no effect on mortality (RD 0.03%, OR 1.02, 95% CI 0.91 to 1.14; 12 studies;
60,684 participants; GRADE: moderate). Compared with placebo, PCSK9 inhibitors increased the risk of any adverse events (RD
1.54%, OR1.08, 95%CI 1.04 to 1.12; 13 studies; 54,204 participants; GRADE: low). Similar effects were observed for the comparison
of ezetimibe and statins: RD 3.70%, OR 1.18, 95% CI 1.05 to 1.34; four studies; 5376 participants; GRADE: low. Clinical event data
were unavailable for the ezetimibe only comparison.
Authors’ conclusions
Over short-term to medium-term follow-up, PCSK9 inhibitors reduced LDL-C. Studies with medium-term follow-up time (longest
median follow-up recorded was 26 months) reported that PCSK9 inhibitors (compared with placebo) decreased CVD risk but may
have increased the risk of any adverse events (driven by SPIRE-1 and -2 trials). Available evidence suggests that PCSK9 inhibitor use
probably leads to little or no difference in mortality. Evidence on relative efficacy and safety when PCSK9 inhibitors were compared
with active treatments was of low to very low quality (GRADE); follow-up times were short and events were few. Large trials with longer
follow-up are needed to evaluate PCSK9 inhibitors versus active treatments as well as placebo. Owing to the predominant inclusion of
high-risk patients in these studies, applicability of results to primary prevention is limited. Finally, estimated risk differences indicate
that PCSK9 inhibitors only modestly change absolute risks (often to less than 1%).
P L A I N L A N G U A G E S U M M A R Y
PCSK9 inhibitors for prevention of cardiovascular disease
Research question
Describe the effectiveness and safety of PCSK9 inhibitors for cardiovascular disease prevention.
Background
Despite the availability of effective drug therapies (statins or ezetimibe) that reduce low-density (LDL) cholesterol (LDL-C), cardiovas-
cular disease (CVD) remains an important cause of mortality and morbidity. Additional LDL-C reduction may therefore be warranted,
especially for patients who are unresponsive to, or are unable to use, existing LDL-C reducing therapies. PCSK-9 inhibition produced
by monoclonal antibodies (PCSK9 inhibitors) may further reduce LDL-C levels and CVD risk.
Study characteristics
Review authors identified 20 studies that evaluated the effects of PCSK9 inhibitors in participants at high risk of CVD; studies were
conducted in outpatient clinic settings. Review authors identified the studies included in this review through electronic literature
searches conducted up to May 2016, and added three large trials published in March 2017.
Key results
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PCSK9 inhibitors constitute a class of drugs that decrease LDL-C and therefore may decrease the incidence of CVD. We examined the
results of 20 studies, which showed beneficial effects on blood cholesterol concentrations of PCSK9 inhibitors at both sixmonths and one
year of follow-up. Although themagnitude of this beneficial effect differed between studies, all showed beneficial effects. In comparisons
of PCSK9 inhibitors versus no PCSK9 inhibitors, current evidence suggests that PCSK9 inhibitors decrease CVD incidence without
affecting the incidence of all-cause mortality. In comparisons of PCSK9 inhibitors versus alternative (more established) treatments such
as statins or ezetimibe, high-quality evidence is lacking. Differences in risk between people treated with and without PCKS9 inhibitors
suggest the absolute treatment benefit will likely be modest (e.g. < 1% change in risk).
Quality of evidence
Most of the included randomised controlled trials (RCTs) were designed to explore biomarker associations; however, as all trials were
industry funded, GRADE assessment revealed that the quality of the evidence was moderate. For associations with clinical endpoints
(mortality and CVD), the quality of the evidence was moderate (placebo comparison) to very low (ezetimibe and statin comparisons).
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
PCSK9 inhibitors compared with placebo in addit ion to stat in and/ or ezet im ibe background care
Patient or population: people at high risk of cardiovascular disease (history of CVD or high LDL-C despite treatment)
Setting: outpat ient care sett ings
Intervention: PCSK9 monoclonal ant ibodies
Comparison: placebo
Outcomes Ilustrative comparative risk or mean (95%
CI)
Relative effect (95%
CI)
M ean difference
(95% CI)
Number of partici-
pants
(studies)
Quality of the evi-
dence
(GRADE)
Comments
Assumed risk or
mean biomarker
using placebo*
Corresponding risk
or mean
using PCSK9 inhibi-
tion†
LDL-C reduct ion
(LDL-C)
Follow-up: 6 months
Mean LDL-C reduc-
t ion was -6.12 mean
percentage change
form baseline
Mean LDL-C reduc-
t ion in the interven-
t ion group was -59.
98 (-64.76 to -55.19)
percentage change
form baseline
-53.86% (-58.64 to
-49.08) in percent-
age reduct ion f rom
baseline
4782
(8 RCTs)
⊕⊕⊕©
MODERATEa
Negative is benef i-
cial
Cardiovascular dis-
ease (CVD)
Follow-up: 6 months
to 36 months
Cardiovascular dis-
ease risk was 64 per
1000 part icipants
Cardiovascular dis-
ease risk in the inter-
vent ion group was
55 (51 lower to 59
lower) per 1000 par-
t icipants
OR 0.86 (0.80 to 0.
92)
59294
(8 RCTs)
⊕⊕⊕©
MODERATEb
Below 1 is benef icial
All-cause mortality
(mortality)
Follow-up: 6 months
to 36 months
All-cause mortality
risk was 18 per 1000
part icipants
All-cause mortality
risk in the inter-
vent ion group was
18 (16 lower to 20
higher) per 1000 par-
t icipants
OR 1.02 (0.91 to 1.
14)
60684
(12 RCTs)
⊕⊕⊕©
MODERATEb
Below 1 is benef icial
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Any adverse events
(adverse events)
Follow-up: 6 months
to 36 months
Risk of any adverse
events was 692 per
1000 part icipants
Risk of any adverse
events in the inter-
vent ion group was
707 (700 higher to
715 higher) per 1000
part icipants
OR 1.08 (1.04 to 1.
12)
61038
(13 RCTs)
⊕⊕©©
LOWb,c
Below 1 is benef icial
CI: conf idence interval
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to the est imate of ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of ef fect but may be substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aUnclear randomisat ion processes and high risk of other biases. Downgrading one level because of ‘‘l im itat ions in the design
and implementat ion of available studies suggest ing high likelihood of bias’’
bResults predominant ly determ ined by 3 large RCTs with a relat ively short median follow-up of 7 months (SPIRE-1), 12
months (SPIRE-2), and 26 months (FOURIER). SPIRE-1/ 2 trials term inated prematurely owing to an unant icipated drug-ant ibody
response. Downgrading one level because of ‘‘indirectness of evidence’’
cEf fect was driven by the discont inued SPIRE trials. Downgrading one level because of ‘‘l im itat ions in the design and
implementat ion of available studies suggest ing high likelihood of bias’’
* Assumed risks or mean LDL-C was based on the comparison arms of included trials
†Corresponding risk or mean was based on the risk dif f erence reported in Table 4 or the mean dif ference in LDL-C
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B A C K G R O U N D
Description of the condition
Cardiovascular disease (CVD), including fatal and non-fatal car-
diac and vascular diseases, remains a major cause of mortality
and morbidity both in the United Kingdom (UK) and globally
(Capewell 2008; Kreatsoulas 2010; Krishnamurthi 2013; Moran
2014; Murray 2012; Roger 2011; WHO 2008). Cardiovascular
disease imposes a serious personal, financial, and societal burden
with estimated direct costs of GBP 14,300,000,000 (i.e. 20% of
National Health Service (NHS) funding), indirect costs of GBP
16,200,000,000, and an attributed mortality percentage of 35%
in the UK (Capewell 2008). This burden is especially high in pa-
tients with familial hypercholesterolaemia (FH) who have loss of
function mutation, which affects 1 in 250 individuals of European
descent (Benn 2012; Knowles 2014; Nordestgaard 2013). These
mutations prevent removal of circulating low-density lipoprotein
cholesterol (LDL-C), which is one of the most important modifi-
able risk factors forCVD(Grundy 2004), both inpatientswith FH
and in the general population. Autosomal dominant FH is caused
by heterozygous mutations in the low-density lipoprotein recep-
tor (LDLR: OMIM #143890) (Sudhof 1985), apolipoprotein B
(APOB; OMIM #144010) - the major constituent apoprotein of
LDL-C (Garcia 2001; Innerarity 1987; Nordestgaard 2013), or
the gene for proprotein convertase subtilisin/kexin type 9 (PCSK9;
#603776) (Abifadel 2003). A rare autosomal recessive form of FH
is caused by mutations in the gene for the low-density lipopro-
tein receptor adaptor protein 1 (LDRRAP1; OMIM #603813).
Patients with FH have higher risk of premature coronary heart
disease that can be reduced with statin treatment. Polygenic eleva-
tion in LDL-C concentration, which is associated with higher risk
of coronary heart disease (CHD), is caused by additive effects of
common, largely independently inherited polymorphisms located
in more than 50 loci throughout the genome (Willer 2013).
Description of the intervention
Interventions of proven efficacy in reducing cardiovascular events
through lowering of LDL-C include statin drugs targeting 3-
hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase and eze-
timibe targeting theNiemann-PickC1-like 1 intestinal cholesterol
transporter protein (Cannon 2015; CTT 2005a; CTT 2005b;
CTT 2012). Cardiovascular risk is reduced but not abolished
among patients receiving these medications, suggesting that ad-
ditional LDL-C reduction via alternative pathways may result in
further reduction in CVD events, especially among patients who
have an inadequate response to, or are intolerant of, statins or eze-
timibe (Mancini 2011; Marks 2003).
A new pharmacological target for further reduction of LDL-C
is the proprotein convertase subtilisin/kexin type 9 (PCSK9) en-
zyme. Monoclonal antibodies (mAbs) against the PCSK9 enzyme
(PCSK9 inhibitors) are currently being evaluated in phase 3 trials.
PCSK9 inhibitors are administered subcutaneously every two or
four weeks. Reported mean half-life times for subcutaneous ad-
ministration have been six to seven days, with minimal differences
due to administration site (abdomen or upper arm) and LDL-C
reaching its lowest level at 15 days (Lunven 2014). The impact, if
any, of environmental factors or comedications on PCSK9 mAb
efficacy is still mostly unknown (Lunven 2014).
How the intervention might work
PCSK9 is synthesised and secreted by hepatocytes and binds to the
LDL-C receptor (LDLR) on the hepatocyte surface, promoting
internalisation and degradation. Reduction in surface LDLR re-
duces uptake of LDL particles and increases LDL-C concentration
in the blood (Cohen 2005; Cohen 2006). Therefore, inhibitors
of PCSK9 are expected to lower LDL-C. Moreover, inhibition of
PCSK9 may further enhance the lipid-lowering effects of statins,
which are thought to be limited by a statin-induced increase in
PCSK9 expression (Catapano 2013).
PCSK9 inhibitors bind to the PCSK9 enzyme with high affinity,
disrupting its ability to bind with LDLR. By preventing PCSK9
from binding to LDLR, inhibitors against PCSK9 maintain sur-
face LDLR expression with the aim of reducing LDL-C serum
concentration. This is supported by the finding that variations in
the PCSK9 gene are associated with long-term elevations in LDL-
C and higher risk of CHD (Benn 2010; Chasman 2012). Alter-
natively, loss of function mutations in PCKS9 that lower LDL-C
levels have also been associated with decreased CHD risk (Cohen
2006). This provides evidence in favour of the PCSK9 enzyme as
a valid therapeutic target for prevention of CVD.
Why it is important to do this review
Statins are widely prescribed to reduce LDL-C levels and CVD
risk in patients at increased risk. Patients taking statins reduce
their risk of CVD by around 20% to 25% for every 1 mmol/
L decrease in LDL-C (CTT 2005a; CTT 2012), which may be
further reduced by taking ezetimibe (Cannon 2015). Given the
strong and positive associations, without clear threshold, between
LDL-C andCVDas described in prospective studies (CTT 2005a;
CTT 2012), it is expected that further reduction in LDL-C may
lead to further prevention of CVD events. This could be especially
important for patients not tolerating statins, those with very high
levels of LDL-C, and those at high cardiovascular risk. Previously,
a narrative review of phase 1 and 2 trials found that PCSK9 in-
hibitors were generally well tolerated (Catapano 2013); however,
information on the medium-term to long-term safety and effi-
cacy of these drugs has not yet been reviewed. Research on statins
seems to suggest the following unintended (safety) endpoints: type
2 diabetes (T2DM), possible weight gain (Sattar 2010; Swerdlow
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2014), liver inflammation, and rarely myositis (Collins 2016). It
is uncertain if reducing LDL-C via a different mechanism might
be associated with the same or a different set of adverse events.
Although a recent meta-analysis (Navarese 2015), which included
the ODYSSEY Long Term trial, showed that PCSK9 inhibitors
indeed reduced LDL-C and cardiovascular-related mortality, this
finding was based mostly on short-term studies (< 24 weeks) and
excluded larger trials with longer follow-up, such as OSLER-1
and OSLER-2 randomised controlled trials (RCTs) and recently
published phase 3 trials (FOURIER and SPIRE-1 and SPIRE-2)
(Sabatine 2015). Furthermore, with recent Food and Drug Ad-
ministration (FDA) and European Medicines Agency (EMA) ap-
provals of alirocumab (Praluent) and evolocumab (Repatha), these
drugs have become available to (selected) patients, and (remaining)
questions on long-term efficacy and safety have become increas-
ingly important to answer. Specifically, the EMA has approved
Praluent and Repatha for patients with primary hypercholestero-
laemia, and the FDA has approved both drugs for patients with
heterozygous familial hypercholesterolaemia or a history of clini-
cal atherosclerotic cardiovascular disease. These recommendations
have found their way into the 2016 European Society of Cardi-
ology (ESC)/European Atherosclerosis Society (EAS) Guidelines
for the Management of Dyslipidaemias, which recommend con-
sideration of a PCSK9 inhibitor for pharmacological treatment of
hypercholesterolaemia “in patients at very high-risk, with persis-
tent high LDL-C despite treatment with maximal tolerated statin
dose, in combination with ezetimibe or in patients with statin in-
tolerance”. The same guidelines recommend that “treatment with
a PCSK9 antibody should be considered in FH patients with
CVD or at very high-risk for CHD” (Catapano 2016). Recently,
Pfizer discontinued the development of bococizumab, citing lack
of long-term efficacy due to increased immunogenicity over time
(Pfizer 2017). Consequently, we considered it timely to conduct a
systematic review of RCTs to quantify the long-term efficacy and
safety of inhibitors of PCSK9 for CVD prevention. For this re-
view, CVD is defined as a composite of fatal and non-fatal cardiac
and vascular diseases, including stroke.
O B J E C T I V E S
Primary
To quantify short-term (24 weeks), medium-term (one year), and
long-term (five years) effects of PCSK9 inhibitors on lipid param-
eters and on the incidence of CVD.
Secondary
To quantify the safety of PCSK9 inhibitors, with specific focus on
the incidence of type 2 diabetes, cognitive function, and cancer.
Additionally, to determine if specific patient subgroups are more
or less likely to benefit from the use of PCSK9 inhibitors.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included parallel-group and factorial RCTs with follow-up
time of at least 24 weeks. Cluster RCTs, cross-over trials, and non-
randomised studies were ineligible for this review, andwe excluded
them during title and abstract screening; we note a single cross-
over trial that we have excluded for this reason (Nissen 2016).
RCTs were eligible if they were reported as full-text articles or were
published as abstracts, or if theywere available only as unpublished
data.
Types of participants
RCTs were eligible if they included adults 18 years of age or older,
with or without a prior history of CVD. Participants could have
normal lipid levels or hypercholesterolaemia. We applied no re-
striction on comorbidities.
Types of interventions
We included trials if they randomised participants to a PCSK9
inhibitor and to placebo, statins, or ezetimibe, or a combination
of these.
Types of outcome measures
Primary outcomes
• Lipid parameters (total cholesterol, LDL-C, high-density
lipoprotein cholesterol (HDL-C), triglycerides, apolipoprotein
A1, apolipoprotein B and lipoprotein(a)): mean difference (MD)
in mean percentage change from baseline or difference at the end
of follow-up
• Composite endpoint of CVD, defined as urgent coronary
revascularisation, unstable angina pectoris, non-fatal and fatal
myocardial infarction, non-fatal and fatal stroke, and CHD death
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Secondary outcomes
• All-cause mortality
• Any adverse events, including type 2 diabetes (T2DM) and
cancer
• Cognitive function as standardised mean difference (SMD),
as mean percentage change from baseline, or as difference
between treatment arms at the end of follow-up
• Fasting glucose and glycosylated haemoglobin (HbA1c) as
mean percentage change from baseline or as difference at the end
of follow-up
• Quality of life as SMD, as mean percentage change from
baseline, or as difference at the end of follow-up
Search methods for identification of studies
Electronic searches
We identified trials through systematic searches (Lefebvre 2011)
of the following databases.
• Cochrane Central Register of Controlled Trials
(CENTRAL; 2016, Issue 4 of 12) in the Cochrane Library.
• MEDLINE (Ovid, 1946 to April week 4 2016).
• Embase (Ovid, 1980 to week 19 2016).
• Web of Science Core Collection (Thomson Reuters, 1970
to 8 May 2016).
Please see Appendix 1 for the search strategies used. We applied
the sensitivity-maximising version of the Cochrane RCT filter (
Lefebvre 2011) to MEDLINE and adaptations of it to Embase
and Web of Science. We limited searches to records from 2005,
as PCSK9 was discovered as a potential target in 2003 (Farnier
2014; Seidah 2003), hence we excluded papers published before
2005. We imposed no language restrictions.
We identified the studies included in this review through elec-
tronic literature searches conducted up to May 2016. Through
these searches, we identified several ongoing studies, and during
the latter stages of finalising the review, we became aware of the
publication of three of them in March 2017. We decided to in-
corporate data from those studies into this version of the review
because of their size and impact on review findings.
Additionally, we searched
ClinicalTrials.gov (www.ClinicalTrials.gov) and theWorld Health
Organization (WHO) International Clinical Trials Registry Plat-
form (ICTRP) Search Portal (apps.who.int/trialsearch/) for rele-
vant RCTs on 18 September 2016.
Searching other resources
We searched the following websites for unpublished studies on 19
September 2016.
• Food and Drug Administration (FDA) website (http://
www.fda.gov/).
• Pharmaceutical company websites (e.g. Regeneron - http://
www.regeneron.com/; Sanofi - http://en.sanofi.com/).
• ProQuest dissertations and theses (PQDT; http://
www.proquest.com/products-services/pqdt.html).
Additionally, we screened reference lists of included studies for
relevant RCTs.
Data collection and analysis
Selection of studies
Two review authors (AFS and LSP) independently screened search
results by title and abstract, and subsequently the full text, for
potentially relevant studies. A third review author (JPC) resolved
disagreements. We distilled multiple reports on a single RCT into
a single entry. We have provided a PRISMA (Preferred Reporting
Items for Systematic Reviews and Meta-Analyses) flow diagram,
as well as details of studies excluded after full text assessment (see
Characteristics of excluded studies).
Data extraction and management
Two review authors (AFS and LSP) independently extracted data
and resolved differences by returning to the original publication
and, if needed, by consulting a third review author (JPC). When
appropriate, we extracted data on numbers of events versus no
events, means, standard deviations, crude point estimates, or stan-
dard error estimates. For continuous endpoints, we extracted data
on change from baseline or on differences between study arms
at completion of follow-up. When possible, we focused on esti-
mates adjusted for baseline measurements (Vickers 2001). When
reported, we extracted results from an intention-to-treat (ITT)
analysis. For adverse events, we tried to extract results for per-
protocol or as-treated populations. When available, we used the
study protocol, appendices and design papers as additional sources
of information. We combined full-text screening, data extraction,
and data entry using a Microsoft Access database (available from
AFS).
Assessment of risk of bias in included studies
We assessed risk of bias using the Cochrane risk of bias tool (
Higgins 2011a) on the basis of the following items.
• Random sequence generation (selection bias).
• Allocation (selection bias).
• Blinding of participants and personnel (performance bias).
• Blinding of outcome assessment (detection bias).
• Incomplete outcome data (attrition bias).
• Selective reporting (reporting bias).
• Other potential sources of bias.
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We graded individual items as having “low”, “unclear”, or “high”
risk of bias. We presented “risk of bias” per study and for the
outcome LDL-C (which can be seen more generally as risk of bias
for biomarker outcomes).
Assessment of bias in conducting the systematic
review
We conducted this Cochrane review according to the published
protocol (Schmidt 2015) and reported deviations from it in the
Differences between protocol and review section.
Measures of treatment effect
We reported results as mean differences (MDs) for continuous
outcomes and as odds ratios (ORs) and risk differences (RDs)
for binary endpoints. In the manuscript, we focus on MDs and
ORs; however, we include estimates of RDs of meta-analysed
treatment effects because of their relevance for individual patients
(Newcombe 2014); given that ORs and RDs represent the same
data, we provide only forest plots for OR estimates and report
pooled RD (and OR) estimates in Table 1 and Table 2. We calcu-
lated confidence intervals (CIs) using theWald method, assuming
a standard normal distribution, or a t-distribution when appro-
priate.
Unit of analysis issues
This Cochrane review focused exclusively on parallel-group de-
signed RCTs, hence we had no unit of analysis issues.
Dealing with missing data
We contacted trial authors to request missing data.
Assessment of heterogeneity
We measured between-study heterogeneity by using the I² statis-
tic with a one-sided confidence interval (with a z-value of -1.96)
and tested it using a Q test. For binary endpoints, we measured
between-study heterogeneity by using Tau² and tested it using a
likelihood ratio test.
Originally, we intended to refrain from meta-analysis if hetero-
geneity was greater than 50%. Although we observed a large
amount of heterogeneity in the biomarker estimates, we never-
theless meta-analysed the data. We made this decision because we
believed that between-study differences in treatment effects did
not preclude a clinically relevant combination of data (see results
and discussion).
Assessment of reporting biases
Fewer than 10 trials reported on the same comparator groups (see
data synthesis and results), hence we did not assess reporting bias.
Data synthesis
Before meta-analysing results, we grouped trials together on the
basis of comparator treatment(s) received, including placebo, eze-
timibe, and ezetimibe or statin. Trials comparing PCSK9 mAbs
against statins only, or comparing mAbs types, were unavailable.
We combined study-specific estimates in R (R Development Core
Team 2014) and combined continuous data using the inverse
variance method for fixed-effect meta-analysis. For binary data,
we reconstructed individual participant data on the basis of cell
counts, and we combined results using generalised linear mod-
els (GLMs) with a random intercept for study (Bradburn 2007;
Sweeting 2004). For continuous data, we reported both fixed-ef-
fect and random-effects estimates, and for binary endpoints, we
reported only fixed-effect estimates, because owing to data sparse-
ness, random-effects models were unreliable.
In the case of multiple treatment or comparator arms, we pooled
estimates across arms to facilitate a comparison between inhibitors
and comparison therapy. Alternatively, we could have compared
results from a single intervention arm versus multiple comparator
groups (or vice versa), but this would have resulted in correlated
effect estimates with erroneously small P values (i.e. increased type
1 errors).
’Summary of findings’ table
We created ’Summary of findings’ tables (using the GRADE ap-
proach to assess the quality of evidence; Grade Working Group
2004) for each comparison group separately and (on the basis of
the protocol) included outcomes, LDL-C, CVD events, adverse
events, and mortality. We calculated risk under the intervention
using estimated mean differences or risk differences; we included
odds ratios in the table but did not use them to calculate (reduced)
risk under treatment. Given that all studies provided participants
with a combination of statins or ezetimibe, we estimated the mean
or risk under the comparison treatment using the entire sample of
trials. We changed column names to reflect this approach.
Subgroup analysis and investigation of heterogeneity
We assessed potential sources of between-study heterogeneity in
PCSK9 inhibitor effects on LDL-C (at six months) using the fol-
lowing subgroup analyses: gender, age, history of CHD, diabetes
at baseline, baseline LDL-C level, and familial or non-familial
hypercholesterolaemia. We calculated interaction effects within
study (Altman 2003) and meta-analysed them, preventing bias
due to study-specific factors (Schmidt 2014b). We explored these
subgroup analyses separately for RCTs comparing PCSK9 mAbs
against placebo or against ezetimibe. Study authors did not report
subgroup effects in sufficient detail for RCTs comparing PCSK9
mAbs against ezetimibe or statin for inclusion in the analysis.
Additionally (owing to the limited number of RCTs, only for tri-
als using a placebo comparator), we employed meta-regression
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(weighted for inverse variance weights; Thompson 2002) to ex-
plore whether between-study heterogeneity was related to baseline
characteristics described before, with the addition of ethnicity and
proportion of missing LDL-C measurements.
Sensitivity analysis
We attempted the following sensitivity analyses.
• We stratified trials by allocated dose of PCSK9 mAb.
Owing to the limited number of trials, we did this only for the
placebo comparison and the endpoints of LDL-C and
apolipoprotein B at six months.
• We intended to explore the influence of perceived risk of
bias by grouping studies that had a low perceived risk of bias on
all items (see Characteristics of included studies) and comparing
six-month LDL-C reduction in studies that did not have low risk
of bias on all items (higher-risk group). However, none of the
trials had low risk of bias on all items, hence we did not perform
this sensitivity analysis.
• We also intended to explore differences due to type of
PCSK9 mAb, but we had already explored this by stratifying
doses for placebo trials. For remaining comparison groups, RCTs
were too few for meaningful exploration of this.
Please note that in our published protocol, we originally set out
to perform these sensitivity analyses for CVD and mortality as
well; however, owing to the limited number of events, we were not
able to perform these analyses. Simillarly, we aimed to explore the
impact of missing data by stratifying RCTs on missing 0% to 5%,
6% to 10%, and more than 10% of LDL-C, CVD, or mortality
data. However, owing to data sparseness, we did this only for the
LDL-C endpoint and used a meta-regression analysis instead.
Reaching conclusions
We based our conclusions on findings derived from quantitative
synthesis of included studies.
R E S U L T S
Description of studies
Results of the search
The search yielded 1066 hits, which we supplemented by 11 addi-
tional records obtained by cross-referencing trial registry sites and
other sources (see Figure 1 for a flow diagram). After screening
titles and abstracts, we retrieved 42 full-text articles and excluded
25 of these.We included 19 references describing 20 studies. Most
studies had multiple publications (e.g. conference abstracts) that
we distilled into a single entry. For the ODYSSEY trials, we ex-
tracted additional information from a recent FDA report (FDA
2015).
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Figure 1. Study flow diagram.
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Included studies
PCSK9 inhibitors; settings and participants
Investigators collected a combined sample of 68,341 participants
in these 20 trials; of these, 1104 participants were included twice
- once in OSLER-1, and once in the meta-analysis of OSLER-1
and OSLER-2 (OLSER-2 was unavailable separately). Of 67,237
unique participants, 20,210 were women (30%; of 67,130 par-
ticipants for whom gender was reported; see Characteristics of
included studies), 6984 did not have a history of CVD (11%; of
61,382 participants with reported CVD history), 2513 had FH
(7%; of 33,707 with reported FH status), 25,536 had a T2DM
diagnosis at baseline (39%; of 65,740 participants with recorded
T2DM status). We note that the three FH studies focused exclu-
sively on participants with FH (self-identified). Caucasians were
the predominant ethnic group included in these studies (86%).
All trials included participants treated in outpatient care settings.
All included studies were industry-sponsored, multi-centre trials;
most focused on alirocumab (REGN727, SAR256553), three ex-
plored bococizumab (RM316, PF-04950615; Ballantyne 2015;
SPIRE 1/2), one examined RG7652 (Equator), and four stud-
ied evolocumab (AMG145). The evolocumab trials (Descartes;
OSLER-1; OSLER 1/2) are closely related in the sense that, after
completing the Descartes study, participants were offered enrol-
ment in the OSLER-2 study. The OSLER-2 has been published
only in combination with OSLER-1 (which similarly limited en-
rolment to participants who first completed a 12-week “parent”
trial). Given that the OSLER-2 trial has not been published sepa-
rately, we includedmeta-analysis results ofOSLER-1 andOSLER-
2, but we also used OLSER-1 data for outcomes not reported in
the meta-analysis of OLSER-1 and OSLER-2 trials.
Comparison group
Investigators in 13 trials randomised participants to placebo
or PCSK9 inhibitors (Ballantyne 2015; Descartes; Equator;
FOURIER; ODYSSEY CHOICE I; ODYSSEY CHOICE II;
ODYSSEY COMBO I; ODYSSEY FH I; ODYSSEY FH II;
ODYSSEY HIGH FH; ODYSSEY Long Term; SPIRE 1/2, with
SPIRE1/2 counted as two studies) as add-on to background ther-
apy, which could consist of ezetimibe, statins, and other interven-
tions (see Characteristics of included studies). They randomised
participants enrolled in ODYSSEY COMBO II and ODYSSEY
MONO to alirocumab or ezetimibe. Finally, the remaining five
studies (OSLER-1; OSLER 1/2; ODYSSEY ALTERNATIVE;
ODYSSEY OPTIONS I; ODYSSEY OPTIONS II) compared
participants receiving a PCSK9 inhibitor with those receiving eze-
timibe or statins, or usual care involving both ezetimibe and statins.
Note that the OPTIONS I and OPTIONS II trials compared
alirocumab with ezetimibe and atorvastatin, atorvastatin, or ro-
suvastatin. As described in the Methods section, to prevent erro-
neously small P values (due to use of the same alirocumab arm
twice), we combined multiple arms of comparison groups and es-
timated effects of alirocumab versus ezetimibe and statin.
Researchers administered PCSK9 inhibitors every two weeks, ev-
ery four weeks, or every eight weeks; for the sake of comparison, we
calculated the two weeks’ equivalence dosage (see Characteristics
of included studies), which ranged from 50 mg to 210 mg every
two weeks. In most studies (except ODYSSEY FH II, ODYSSEY
HIGH FH, DESCARTES, OSLER-1, and ODYSSEY LONG
TERM), participants received different dosages of PCSK9, often
depending on a predefined up-titration criterion such as LDL-C
reduction or history of CVD; to account for these within-study
differences in dosage by stratified analyses (see methods and re-
sults), we grouped studies (when needed) by using a dosage range
instead of a single dosage.
Excluded studies
We excluded 25 trials (Characteristics of excluded studies), pre-
dominantly owing to follow-up time less than 24 weeks (see main
objectives), or because trials described a meta-analysis while pro-
viding little to no detail on individual studies (which were already
included separately). Besides these excluded trials, we identified
seven ongoing trials (Characteristics of ongoing studies) that fit
our inclusion criteria; of these, two trials (ODYSSEY Outcomes;
TAUSSIG) focus on long-term effects on clinical outcomes, and
one describes the six SPIRE biomarker trials and is pending clas-
sification.
Risk of bias in included studies
We have provided per study risk of bias with rationale in the
Characteristics of included studies table. All studies described
used a randomised trial design; we have discussed risk of bias
for biomarker endpoints in the following sections and have sum-
marised this information in Figure 2 and Figure 3, See section
on “Detection and attrition bias of the association with clinical
endpoints” for risk of bias reflecting clinical endpoints.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Six trials (Equator; ODYSSEY ALTERNATIVE; ODYSSEY
CHOICE I; ODYSSEY CHOICE II; ODYSSEY COMBO I;
ODYSSEYMONO) did not provide sufficient detail on how ran-
domisation was achieved (unclear risk of bias). The remaining
studies typically used a voice-based or Internet-based centralised
response system, and we perceived them to have low risk of bias.
We ensured allocation concealment by using centralised alloca-
tion and in some cases permuted blocks. Five RCTs (Ballantyne
2015; Equator; ODYSSEY CHOICE I; ODYSSEY CHOICE II;
ODYSSEY COMBO I) did not sufficiently report on this item,
and we perceived them as having unclear risk of bias (we contacted
study authors but they did not respond).
Blinding
Owing to the open-label design, the OSLER-1 and OSLER-2
studies are at high risk of performance bias. It seems plausible that
knowledge of drug exposure may influence choices on lifestyle or
additional clinical care, whichmay distort difference in biomarkers
and clinical events across treatment arms.
Most studies assessed biomarkers in a central laboratory, making
detectionbias unlikely; one possible exception is the Equator study,
which did not describe how biomarkers were assessed.
Incomplete outcome data
Loss due to follow-up (attrition bias) was typically low (arbitrarily
defined as < 5%), except in the Descartes, Equator, ODYSSEY
ALTERNATIVE,ODYSSEYCOMBO I,ODYSSEYLong Term,
and OSLER-1 trials, and in meta-analysis of OSLER 1/2. Most
studies used advanced analytics, such as mixed-effects models or
(multiple) imputations, to ameliorate loss due to follow-up (even
if this was minor) and to ensure the ITT analysis. However, infor-
mation on both performance of these methods and appropriate-
ness of assumptions underlying these methods was missing.
Selective reporting
We compared endpoints described in study protocols and on clin-
icaltrials.gov versus endpoints reported in the primary publica-
tion, and general found good agreement. We assigned seven tri-
als (contributing 2901 participants) an unclear risk of bias grade
because the full publication was unavailable, hence we could not
fully compare results.
Other potential sources of bias
In accordancewith guidance provided byCochrane (Lundh 2017),
we assigned high risk of bias to all industry-funded trials.
Detection and attrition bias of association with
clinical endpoints
Most studies reported clinical endpoints based on the safety sam-
ple, typically defined as the sample that received at least one
dose of the allocated study drug, and not the sample randomised.
Especially worrisome were the Descartes, Equator, ODYSSEY
ALTERNATIVE,ODYSSEYCOMBO I,ODYSSEYLong Term,
and OSLER-1 trials, which, as described, had considerable at-
trition. Positive exceptions were the SPIRE-1, SPIRE-2, and
FOURIER trials, which were specifically designed to explore clin-
ical endpoints, used the ITT sample, and report small numbers of
participants lost to follow-up. Although potential lack of blind-
ing seems unlikely to bias biomarker measurements, it may pose
a considerable source of bias for detection of clinical endpoints.
Of particular concern are the OSLER-1 and OSLER-2 studies,
which were open-label trials (high risk of bias); however, other
studies did not always adequately explain how clinical endpoints
were detected and how detection bias was prevented (unclear risk
of bias; see Characteristics of included studies).
Effects of interventions
See: Summary of findings for the main comparison Summary
of findings for PCSK9 compared with placebo; Summary of
findings 2 Summary of findings for PCSK9 compared with
ezetimibe; Summary of findings 3 Summary of findings for
PCSK9 compared with ezetimibe and statins
See ’Summary of findings’ tables for the following.
• PCSK9 mAb against placebo (Summary of findings for the
main comparison).
• PCSK9 mAb against ezetimibe and statins (Summary of
findings 2).
• PCSK9 mAb against ezetimibe (Summary of findings 3).
Biomarker effects in comparison of PCSK9 mAb
against placebo at six months
At six months follow-up, the effect of PCSK9 inhibitors on LDL-
C compared with placebo was noted as -53.86% (95% CI -58.64
to -49.08; eight studies; 4782 participants; GRADE: moderate)
reduction from baseline (Figure 4) (see Table 3 and Appendix 2 for
remaining forest plots). Review authors observed similar reduc-
tions for triglycerides (-11.39%, 95% CI -17.04 to -5.74); total
cholesterol (-31.41%, 95% CI -43.65 to -19.16); apolipoprotein
B (-41.93%, 95% CI -49.76 to -34.10); lipoprotein(a) (-19.80%,
95% CI -25.43 to -14.17); and non-HDL-C (-47.17%, 95% CI -
53.92 to -40.42) (seeTable 3). Treatment effect estimates onHDL-
C and apolipoprotein A1 at six months were as follows: 6.00, 95%
CI 4.31 to 7.69; and 3.50%, 95% CI 2.37 to 4.64, respectively.
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Findings of two studies reveal that the association with HbA1c,
as absolute change from baseline, was 0.01% (95% CI -0.06 to
0.08).
Figure 4. Association of PCSK9 inhibitors compared with placebo with mean percentage change from
baseline in LDL-C at six months.
Biomarker effects in comparison of PCSK9 mAb
against ezetimibe and statins at six months
Compared with those given ezetimibe and statins, participants re-
ceiving PCSK9 inhibitors showed a reduction (percentage change
from baseline) of -39.20% in LDL-C (95% CI -56.15 to -22.26;
five studies; 5376 participants; GRADE: moderate) (Figure 5); -
3.47% (95% CI -8.26 to 1.32) in triglycerides; -26.72% (95%
CI -30.26 to -23.19) in apolipoprotein B; -19.51% (95% CI -
24.48 to -14.53) in lipoprotein(a); -28.19% (95% CI -32.79 to
-23.59) in non-HDL-C, and 6.42% (95% CI 1.31 to 11.52) in
HDL-C (see Table 3 and Appendix 2 for remaining forest plots).
No information was available on total cholesterol, apolipoprotein
A1, or HbA1c.
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Figure 5. Association of PCSK9 inhibitors compared with ezetimibe and statins with mean percentage
change from baseline in LDL-C at six months.
Biomarker effects in comparison of PCSK9 mAb
against ezetimibe at six months
Two trials (ODYSSEY COMBO II; ODYSSEY MONO) evalu-
ated PCSK9 mAb against ezetimibe and reported the following
effects (percentage change from baseline) on biomarkers: -30.20%
(95%CI -34.18 to -26.23; two studies; 823 participants;GRADE:
moderate) for LDL-C (Figure 6); -0.43% (95% CI -4.90 to 4.03)
for triglycerides; -15.84% (95% CI -19.37 to -12.30) for total
cholesterol; -13.69% (95%CI -30.60 to 3.21) for lipoprotein(a); -
23.18% (95%CI -26.28 to -20.08) for apolipoprotein B; -23.45%
(95% CI -27.07 to -19.83) for non-HDL-C; 7.01% (95% CI
3.70 to 10.32) for HDL-C; and 6.13% (95% CI 4.34 to 7.91) for
apolipoprotein A1. Information on HbA1c was unavailable.
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Figure 6. Association of PCSK9 inhibitors compared with ezetimibe with mean percentage change from
baseline in LDL-C at six months.
Biomarker effects of PCSK9 mAb after one year
At one year, effect estimates of PCSK9 inhibitors versus placebo
were available for six trials (Descartes; FOURIER; ODYSSEY
COMBO I; ODYSSEY Long Term; SPIRE 1/2, with SPIRE1/2
counted as two studies) and generally showed similar effect esti-
mates as for six months: -52.87% (95% CI -60.03 to -45.72) for
LDL-C; -28.47% (95%CI -38.85 to -18.10) for total cholesterol;
-12.53% (95% CI -15.45 to -9.61) for triglycerides; -43.51%
(95% CI -48.88 to -38.13) for apolipoprotein B; 3.00% (95% CI
1.31 to 4.69) for apolipoprotein A1; -43.46% (95% CI -57.45
to -29.47) for non-HDL-C; and 6.06% (95% CI 4.30 to 7.82)
for HDL-C. Associations with glucose and HbA1c were 1.80 mg/
dL (95% CI 0.61 to 2.99) and 0.02% (95% CI -0.01 to 0.05).
Results for other biomarkers were unavailable.
Themeta-analysis (OSLER 1/2) provided estimates at one year for
PCSK9 mAbs compared with ezetimibe and statins, again report-
ing similar effect estimates as before (see Table 4 and Appendix 2
for remaining forest plots). Studies comparing PCSK9 inhibitors
against ezetimibe did not follow participants up to one year.
Exploration of between-study heterogeneity
Generally, between-study heterogeneity (measured as I²) in treat-
ment response was high. To explore this, we performed the fol-
lowing subgroup analyses on LDL-C and apolipoprotein B.
Grouping studies with similar PCSK9 dosages (Included studies)
compared with placebo at six months follow-up resulted in mean
percentage changes in LDL-C of -54.37% (95% CI -59.14 to -
49.60) for bi-weekly 75 to 150 mg mAbs; -51.95% (95% CI -
63.73 to -40.17) for bi-weekly 150 mg mAbs; and -54.00% (95%
CI -77.46 to -30.54) for bi-weekly 50 to 200 mg mAbs compared
with the overall effect in all RCTs combined of -53.86% (95%
CI -58.64 to -49.08) (see Figure 7). Mean percentage changes
in apolipoprotein B were -40.99% (95% CI -50.78 to -31.20)
for biweekly 75 to 150 mg mAbs; -41.74% (95% CI -55.22 to -
28.26) for biweekly 150 mg mAbs; and -45.50% (95% CI -65.27
to -25.73) for biweekly 50 to 200 mg mAbs compared with the
overall effect in all RCTs combined of -41.93% (95% CI -49.76
to -34.10) (see Figure 8). Between-study heterogeneity persisted
despite grouping of RCTs administering similar dosages and re-
porting no clear dose-response effect (increasing effectiveness).
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Figure 7. Sensitivity analyses grouping RCTs by PCSK9 dose compared with placebo on 6 months LDL-C
mean percentage change from baseline.
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Figure 8. Sensitivity analyses grouping RCTs by PCSK9 dose compared with placebo on 6 months
apolipoprotein B mean percentage change from baseline.
To further explore sources of between-study heterogeneity, we
meta-analysed reported subgroup effect estimates on PCSK9
mAbs compared with placebo on six months mean percent-
age change in LDL-C (Figure 9). These analyses suggested that
some between-study heterogeneity may be explained by more
pronounced effects in participants who were 65 years of age or
younger, had a body mass index (BMI) of 30 or greater, or had a
history of T2DM.High baseline levels of LDL-C and total PCSK9
seemed to be related to treatment response but were available for
only a single trial (ODYSSEY Long Term). We performed simi-
lar analyses for trials comparing PCSK9 inhibitors versus ezetim-
ibe, but with a maximum sample size of two RCTs, results were
imprecise (Figure 10). Finally, using meta-regression (Figure 11),
we found that the proportion of Caucasians and the proportion
of participants for whom follow-up LDL-C measurements were
missing were related, and effects of PCSK9 inhibitors on mean
percentage change in LDL-C were increased. However, these es-
timates became non-significant after correction for unexplained
between-study heterogeneity based on a random-effects model.
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Figure 9. Subgroup and interaction effects of six months mean percentage change in LDL-C for PCSK9
trials using a placebo comparison arm.
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Figure 10. Subgroup and interaction effects of six months mean percentage change in LDL-C for PCSK9
trials using a ezetimibe comparison arm.
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Figure 11. Meta-regression of PCSK9 mAbs compared with placebo at six months mean percentage change
in LDL-C. The long dashed line represents the fixed effect, the long-short dashed line random effects, circle
diameter is proportionate to the inverse of the variance (i.e. equal to study precision).
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PCSK9 effects on clinical endpoints in comparison
with placebo
Owing to the fact that original publications did not report treat-
ment effect estimates with clinical endpoints over time, results on
clinical endpoints (summarised in Table 1 and Table 2) are based
on the maximum follow-up available.
Odds ratio estimates of PCSK9 inhibitors compared with placebo
with intended effects were as follows: OR 1.02 (95% CI 0.91
to 1.14; 12 studies; 60,684 participants; GRADE: moderate) for
all-cause mortality; OR 0.86 (95% CI 0.80 to 0.92; eight stud-
ies; 59,294 participants; GRADE: moderate) for any CVD event
(Figure 12);OR0.77 (95%CI 0.69 to 0.85) for anymyocardial in-
farction (MI); and OR 0.76 (95% CI 0.65 to 0.89) for any stroke.
Treatment effect estimates of unintended effects were as follows:
OR 1.08 (95% CI 1.04 to 1.12; 13 studies; 61,038 participants;
GRADE: low) for any adverse events (Figure 13); OR 1.07 (95%
CI 0.99 to 1.16) for myalgia; OR 1.19 (95% CI 0.91 to 1.55)
for influenza; OR 0.86 (95% CI 0.62 to 1.18) for hypertension;
OR 0.91 (95% CI 0.63 to 1.31) for any cancer diagnosis; OR
1.04 (95% CI 0.95 to 1.14) for T2DM; OR 0.85 (95% CI 0.73
to 0.99) for elevated creatinine; and OR 1.04 (95% CI 0.88 to
1.24) for neurological events. Exclusion of terminated SPIRE-1/2
- bococizumab - trials from any adverse events and myalgia meta-
analyses resulted in attenuated effect estimates of OR 1.01 (95%
CI 0.96 to 1.06) and OR 1.17 (95% CI 0.87 to 1.56). Evaluation
of these treatment effect estimates on the RD scale revealed that
the effect of PCSK9 inhibitors on the risk of an event was typically
modest, with changes in risk often less than 1% (see Table 2).
Figure 12. Association of PCSK9 inhibitors compared with placebo with the incidence of any CVD.
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Figure 13. Association of PCSK9 inhibitors compared with placebo with the incidence of any adverse events.
PCSK9 effects on clinical endpoints in comparison
with ezetimibe and statins
Odds ratio estimates of PCSK9 inhibitors compared with ezetim-
ibe and statins with intended effects were as follows: OR 0.45
(95% CI 0.27 to 0.75; three studies; 4770 participants; GRADE:
very low) for any CVD event (Figure 14 data on all-cause mor-
tality and any MI were unavailable. Treatment effect estimates
with unintended effects were as follows: OR 1.18 (95% CI 1.05
to 1.34; five studies; 5376 participants; GRADE: low) for any
adverse events (Figure 15); OR 1.09 (95% CI 0.81 to 1.48) for
myalgia; OR 1.28 (95% CI 0.91 to 1.80) for influenza; OR 1.10
(95% CI 0.41 to 2.96) for hypertension; OR 1.10 (95% CI 0.63
to 1.93) for T2DM, OR 0.51 (95% CI 0.28 to 0.92) for elevated
creatinine; and OR 1.22 (95% CI 0.40 to 3.69) for neurological
events. Data for any stroke and for cancer were unavailable.
Figure 14. Association of PCSK9 inhibitors compared with ezetimibe and statins with the incidence of any
CVD.
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Figure 15. Association of PCSK9 inhibitors compared with ezetimibe and statins with the incidence of any
adverse events.
Evaluation of these estimates on the RD scale revealed that effects
of PCSK9 inhibitors on risks of an event were typically modest;
changes in risk often were less than 1% (see Table 2).
Outcomes and comparisons without data
See respective sections for details on missing outcome data that
were unavailable for some comparisons. Clinical outcome data
were insufficiently available to perform a meta-analysis for com-
parison with ezetimibe. Data on quality of life were unavailable for
all studies. Although the substudy of the FOURIER - EBBING-
HAUB - presented little or no effect on cognitive function, these
data had not been published in sufficient detail to be included
here. Regardless of the publication status of the EBBINGHAUB
trial, data on cognitive function were not published by other tri-
als, hence we decided (post hoc) to extract data on neurological
events.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
PCSK9 Inhibitors compared to ezet im ibe.
Patient or population: people at high risk of cardiovascular disease (history of CVD or high LDL-C despite treatment)
Setting: outpat ient care sett ings
Intervention: PCSK9 monoclonal ant ibodies
Comparison: ezet im ibe
Outcomes Ilustrative comparative risk or mean (95%
CI)
Relative effect
(95%CI)
M ean difference
(95% CI)
Number of partici-
pants
(studies)
Quality of the evi-
dence
(GRADE)
Comments
Assumed risk or
mean biomarker
using ezetimibe*
Corresponding risk
or mean
using PCSK9 inhibi-
tion†
LDL-C reduct ion
(LDL-C)
Follow up: 6 months
Mean LDL-C reduc-
t ion was -6.12 mean
percentage change
form baseline
Mean LDL-C reduc-
t ion in the interven-
t ion group was -36.
32 (-40.29 to -32.34)
percentage change
f rom baseline
-30.20% (-34.18 to
-26.23) in percent-
age reduct ion f rom
baseline
823
(2 RCTs)
⊕⊕⊕©
MODERATEa
Negative is benef i-
cial
Cardiovascular dis-
ease (CVD)
Cardiovascular dis-
ease risk was 64 per
1000 part icipants
Data unavailable
All-cause mortality
(mortality)
All-cause mortality
risk was 6 per 1000
part icipants
Data unavailable
Any adverse events
(adverse events)
Risk of any adverse
events was 692 per
1000 part icipants
Data unavailable
CI: conf idence interval27
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GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to the est imate of ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of ef fect but may be substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aHigh risk of other biases. Downgrading one level because of ‘‘l im itat ions in the design and implementat ion of available
studies suggest ing high likelihood of bias’’
∗Assumed risks or mean LDL-C was based on the comparison arms of included trials
†Corresponding risk or mean was based on the risk dif f erence reported in Table 4 or the mean dif ference in LDL-C.
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PCSK9 inhibitors compared with ezet im ibe and stat ins
Patient or population: people at high risk of cardiovascular disease (history of CVD or high LDL-C despite treatment)
Setting: outpat ient care sett ings
Intervention: PCSK9 monoclonal ant ibodies
Comparison: ezet im ibe and stat ins
Outcomes Ilustrative comparative risk or mean (95%
CI)
Relative effect
(95%CI)
M ean difference
(95% CI)
Number of partici-
pants
(studies)
Quality of the evi-
dence
(GRADE)
Comments
Assumed risk or
mean biomarker
with ezetimibe and
statins*
Corresponding risk
or mean
with PCSK9 inhibi-
tion†
LDL-C reduct ion
(LDL-C)
Follow-up: 6 months
Mean LDL-C reduc-
t ion was -6.12 mean
percentage change
form baseline
Mean LDL-C reduc-
t ion in the interven-
t ion group was -45.
32 (-62.27 to -28.37)
percentage change
form baseline
-39.20% (-56.15 to
-22.26) in percent-
age reduct ion f rom
baseline
5376
(5 RCTs)
⊕⊕⊕©
MODERATEa
Negative is benef i-
cial
Cardiovascular dis-
ease (CVD)
Follow-up: 6 months
to 11 months
Cardiovascular dis-
ease risk was 64 per
1000 part icipants
Cardiovascular dis-
ease risk in the inter-
vent ion group was
53 (47 lower to 60
lower) per 1000 par-
t icipants
OR 0.45 (0.27 to 0.
75
4770
(3 RCTs)
⊕©©©
VERY LOWa,b,c
Below 1 is benef icial
All-cause mortality
(mortality)
All-cause mortality
risk was 6 per 1000
part icipants
Data unavailable
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Any adverse events
(adverse events)
Follow-up: 6 months
to 11 months
Risk of any adverse
events was 692 per
1000 part icipants
Risk of any adverse
events in the inter-
vent ion group was
729 (703 lower to
755 higher) per 1000
part icipants
OR 1.18 (1.05 to 1.
34)
5376
(5 RCTs)
⊕⊕©©
LOWa,b
Below 1 is benef icial
CI: conf idence interval
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to the est imate of ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of ef fect but may be substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aMost data were based on OSLER-1 and/ or OSLER-2, which were open-label studies. Downgrading one level because of
‘‘l im itat ions in the design and implementat ion of available studies suggest ing high likelihood of bias’’
bITT results were of ten unavailable; instead data were extracted on the basis of an as treated sample. Downgrading one level
because of ‘‘l im itat ions in the design and implementat ion of available studies suggest ing high likelihood of bias’’
cNumber of events was low. Downgrading one level because of ‘‘ Imprecision of results’’
* Assumed risks or mean LDL-C was based on comparison arms of included trials
†Corresponding risk or mean was based on the risk dif f erence reported in Table 4 or the mean dif ference in LDL-C
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D I S C U S S I O N
Summary of main results
In this systematic review and meta-analysis, we showed that ran-
domised trials evaluating PCSK9 inhibitors (primarily against
placebo) had a beneficial profile in terms of cardiovascular risk
factors that most likely explain their protective effects on cardio-
vascular events.
In terms of cardiovascular biomarkers, treatment with PCSK9 in-
hibitors was characterised by a decrease in low-density lipoprotein
cholesterol (LDL-C), apolipoproteinB, non-high-density lipopro-
tein cholesterol (HDL-C), triglycerides, and lipoprotein(a), and a
modest increase in HDL-C and apolipoprotein A1. Investigators
reported some differences in biomarker response depending on
the use of placebo or active comparisons.
Although we observed high between-study heterogeneity for
biomarker outcomes,most study authors agreed on direction of ef-
fect anddeemed that differences inmagnitudewere similar enough
to provide clinically relevant treatment effect estimates. We did
not observe a dose-response effect of PCSK9 inhibitors on LDL-
C or apolipoprotein B when comparing trials with similar PCSK9
monoclonal antibody (mAb) dosages. A dose-response effect may
have been due to the crude categorisation used by review authors
and/or to grouping of studies by different comparator drugs or by
other differences in study-specific factors.
Trials published to date comparing PCSK9 inhibitors against
placebo showed potentially little to no effect on all-cause mortal-
ity; nevertheless, PCSK9 inhibitors showed protective effects on
cardiovascular disease (CVD) events, myocardial infarction (MI),
and any stroke. Treatment with PCSK9 inhibitors was associated
with a modest increase in the risk of any adverse events (odds ratio
(OR) 1.08, 95% confidence interval (CI) 1.04 to 1.12), largely
driven by the SPIRE-1 and SPIRE-2 trials, which used an agent
that was discontinued owing to immunogenicity. When looking
at specific adverse events (extracted in this systematic review), we
found that compared with placebo, PCSK9 inhibitors did not
show significant association with type 2 diabetes (T2DM), can-
cers, or neurocognitive events, possibly as the result of limited fol-
low-up duration. It is important to note that recent phase 3 trials
(FOURIER, SPIRE-1, and SPIRE-2) did not report on cancer.
Regarding minor adverse events, PCSK9 inhibitors showed poten-
tially increased risk of myalgia and influenza, with the former be-
coming non-significant after the SPIRE-1/2 trials were excluded.
Study authors reported that they observed a protective effect with
PCSK9 inhibitors, which decreased the risk of elevated creatinine
(compared with placebo and active treatments). Trials compar-
ing PCSK9 inhibitors against ezetimibe and statins described a
more pronounced protective effect on CVD risk when compared
with placebo; this discrepancy is likely related to the lower quality
of evidence. Researchers provided no data on all-cause mortality,
stroke, or MI. Information on clinical endpoints was unavailable
for the ezetimibe only comparison.
Estimation of the same associations on a risk difference scale (Table
4) revealed that PCSK9 inhibitors only modestly changed the
outcome risk, often with less than 1% change in risk.
Overall completeness and applicability of
evidence
Given selection criteria and study designs reported by published
trials evaluating PCSK9 inhibitors, we consider it important to
highlight situations that may limit the applicability of existing
evidence.
First, most of the evidence was obtained from people with estab-
lished atherosclerotic CVDor at high risk of cardiovascular events;
therefore evidence regarding the use of PCSK9 inhibitors for pri-
mary prevention remains controversial. Second, information on
clinical endpoints for the placebo comparison was based on the
large sample size in the FOURIER and SPIRE-1 and SPIRE-2
trials. Although these trials were large, median follow-up was less
than three years, hence information on long-term efficacy and sa-
fety is absent. For the other comparisons, follow-up was shorter
and events were fewer, prohibiting any strong recommendations
at this time. Third, information on the safety of PCSK9 inhibitors
did not reveal an increase in risk of cancer or T2DM. However,
the largest trials to date (FOURIER and SPIRE-1 and SPIRE-
2) did not provide cancer data, and again, follow-up time was
very modest, leaving questions on long-term effectiveness and risk
unanswered. Three recent genetic studies with large sample size
and long-term follow-up showed that variation in the PCSK9 lo-
cus was associated with increased glucose and T2DM (Ference
2016; Lotta 2016; Schmidt 2017). Lack of significant association
with T2DMmay be due to the relatively small number of T2DM
events collected to date (< 2000) as a comparison; the association
of statins with T2DM was discovered only after more than 4000
events were reported (Swerdlow 2014).
Quality of the evidence
Although all available data were derived from industry-sponsored
randomised controlled trials (RCTs), most trials seemed to have
low risk of bias. Exceptions are the open-labelOSLER trials, which
were at high risk of performance bias. Another important poten-
tial source of bias was attrition bias, whereby some RCTs included
missing observations for more than 5% of enrolled participants.
Most trials tried to minimise this bias by using advanced analyt-
ics that explicitly (multiple imputation) or implicitly (mixed-ef-
fects models) imputed these missing observations, thus ensuring
that all comparison were made on an intention-to-treat (ITT) ba-
sis. The appropriateness of these models (and their underlying as-
sumptions) was not reported, hence these imputation algorithms
may have failed to correct for potential attribution bias. For the
placebo comparison, however, the large number of participants in
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the FOURIER and SPIRE-1/2 trials had very low attrition rates
and generally were perceived to have low risk of bias.
The quality of evidence was high for the biomarker endpoints
in comparison with placebo or ezetimibe. For the comparison of
PCSK9 mAbs against ezetimibe and statins, we graded quality as
moderate owing to inclusion of the open-label OSLER trials. De-
spite theGRADE (GradeWorkingGroup 2004) recommendation
to downgrade evidence associated with high between-study het-
erogeneity, we decided against this approach because most studies
(i.e. LDL-C outcomes) reported the same direction of effects.Het-
erogeneity reflected a difference in magnitude - not in direction
of effect (confirmed by clinical experts JPC and ADH). Further-
more, use of random-effects models resulted in point estimates
and confidence intervals that are free of bias (Thompson 1999),
even in the presence of heterogeneity. Although we believe that
this between-study heterogeneity should not be reflected in our
GRADE score, it does reflect a potential need for personalised
medicine (Schmidt 2016).
For intended effect and clinical outcomes (i.e. CVD, all-cause
mortality, and MI) with PCSK9 inhibitors compared with
placebo, we graded the quality of the evidence asmoderate. Results
were derived from three trials with large sample sizes (FOURIER,
SPIRE-1 and -2), two of which used the terminated bococizumab
drug. Furthermore, median follow-up was less than three years,
hence long-term effectiveness and safety remain uncertain, po-
tentially influencing the absence of an effect on all-cause mortal-
ity or other outcomes with longer lag time. We graded the qual-
ity of the evidence as very low in the PCSK9 mAb-to-ezetimibe
and statin comparison, again owing to inclusion of the open-label
OSLER trials. Bias due to unblinded allocation may explain the
likely overly large effect of PCSK9 inhibitors against ezetimibe and
statins on CVD events (OR 0.45, 95 CI% 0.27 to 0.75) versus
PCSK9 mAb against placebo (OR 0.86, 95% CI 0.0.80 to 0.92).
Given the reported antibody drug response, inclusion of the dis-
continued bococizumab trials may seem controversial. However,
owing to the limited large sample size of trials with modestly long
follow-up, we decided to include these data. Side effects may dif-
fer between PCSK9 inhibitors, for example, the potential myal-
gia effect in the placebo comparison seemed more pronounced
in the SPIRE-1 and SPIRE-2 trials than in the FOURIER trials
(evolocumab). Owing to the limited number of adequately sam-
pled trials, we could not perform formal analyses.
Potential biases in the review process
The meta-analysis presented may show some weaknesses. First,
meta-analyses explored a large number of endpoints, increasing
the probability of a false positive finding. We did not correct for
multiple testing because we sought to inform ongoing trials, which
can act as an independent and final arbiter. Second, despite our
best efforts, wemay have failed to identify certainPCSK9 inhibitor
trials. Given that we are unaware of the results of any uniden-
tified RCTs, this seems unlikely to bias our results but will ob-
viously reduce sample size. Third, although we set out to report
effect estimates with clinical endpoints, similar to biomarker end-
points, at six months, one year, and five years of follow-up, we
found that this was impossible owing to the limited sample size
and the fact that the original RCT did not present data in suffi-
cient detail. Fourth, we did not present data by type of PCSK9
inhibitor because of the limited sample size and the focus of tri-
als on alirocumab, making such an analysis uninformative at the
moment. Fifth, effect estimates of PCSK9 compared with ezetim-
ibe and statin may be further biased by the limited number of
events influencing both point estimates and confidence intervals
(Bradburn 2007; Sweeting 2004).We tried to deal with this poten-
tial source of bias by re-creating individual participant data (based
on reported cell frequencies) and by estimating a combined effect
by using a mixed-effect model with random intercept (and slope)
for study indicator. Nevertheless, we found that random-effects
models (mixed-effect model with random intercept and slope) of-
ten did not converge, hence we did not report these estimates.
Given the large sample size included in FOURIER and SPIRE-
1 and SPIRE-2 trials for the placebo comparison, sparse data are
less of an issue for effect estimates on major CVD events but re-
main inconclusive for rarer CVD and non-CVD events such as
haemorrhagic stroke, cancers, andT2DM. Furthermore, although
the FOURIER and SPIRE trials collected data on a large number
of participants, investigators provided relatively short follow-up
times, leaving open the question of long-term efficacy and safety.
Agreements and disagreements with other
studies or reviews
We are aware of two previous systematic reviews and meta-analy-
ses on PCSK9 inhibitors (Navarese 2015; Zhang 2015); both in-
cluded a large number of RCTs with short follow-up of 12 weeks,
which we excluded here, as well as several longer-term follow-up
studies that we included.
The meta-analysis of Zhang 2015 revealed a protective effect on
mortality of alirocumab versus placebo (OR 0.43, 95%CI 0.19 to
0.96) and of alirocumab versus ezetimibe (OR 0.48, 95% CI 0.16
to 1.45); these effects are different from the more neutral effect
that we observed (OR 1.02, 95%CI 0.91 to 1.14). This difference
may have occurred because Zhang 2015 relied predominantly on
short-term follow-up studies, limiting the number of events per
study, and this likely biased effect estimates.
Similar to this review, Zhang found a protective effect of
alirocumab on elevated creatine kinase versus placebo (OR 0.72,
95% CI 0.52 to 1.01) and versus ezetimibe (OR 0.75, 95% CI
0.46 to 1.24). Review authors found a similar protective effect
of elevated creatine kinase for evolucumab (vs placebo or eze-
timibe), as well as protective effects of elevated alanine amino-
transferase and aspartate aminotransferase (no information was re-
ported on mortality for evolucumab). Contrary to our meta-anal-
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yses, Zhang 2015 found a non-significant decrease in influenza
for both alirocumab and evolucumab. Results may be concordant
with a null effect, as in both Zhang’s review and ours, these as-
sociations did not reach significance at an alpha of 0.05. Alterna-
tively, Zhang included trials with only a few weeks of follow-up,
potentially excluding the annual influenza season, and the shorter
duration of exposure conveys less risk.
Navarese 2015 reported a protective effect of PCSK9 inhibitors (vs
all types of comparators) for all-causemortality (OR 0.45, 95%CI
0.23 to 0.86) and a decreased incidence of increased serum creatine
kinase levels (OR 0.72, 95% CI 0.54 to 0.96), as well as protective
effects for cardiovascular mortality and MI (OR 0.50, 95% CI
0.23 to 1.10; OR 0.49, 95% CI 0.26 to 0.93, respectively). As
with the Zhang 2015 study, results were based onmany short-term
trials with very few events per study, hence the caveats described
before continue to hold.
Finally, we are aware that a recent network meta-analysis (Lipinski
2016) indirectly comparing mAb versus placebo showed an OR
for neurocognitive adverse events of 2.34 (95% CI 1.11 to 4.93).
This association was not observed in the current meta-analyses,
which directly compared PCSK9 inhibitors versus placebo and
therefore were less susceptible to bias.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Moderate-quality evidence shows that PCSK9 inhibitors decrease
LDL-C and related lipid biomarkers on a short-term (24 weeks)
and medium-term (one year) basis (GRADE: moderate). When
compared against placebo, PCSK9 inhibitors reduce risks of CVD,
MI, and any stroke (GRADE: moderate); however, owing to lim-
ited follow-up (< 3 years) and few adequately sampled trials (three
with large samples), information on long-term safety and efficacy
is lacking.
Effects of PCSK9 inhibitors compared with statin and ezetimibe
were of lower quality (GRADE: low to very low), mainly because
the number of events per RCT was limited. Additionally, some
trials had perceived high risk of bias as the result of incomplete
follow-up, and others were not adequately blinded (OSLER stud-
ies). Both comparisons revealed an increase in any adverse events
(GRADE: low), which, in the placebo compassion, was driven by
SPIRE-1 and SPIRE-2 results. Evidence found to date shows no
effect on type 2 diabetes and cancers, but the SPIRE-1 and SPIRE-
2 trials reported an increase in glucose. Additionaly, we observed
an unexpected decrease in the incidence of elevated creatine in the
PCSK9 inhibitor arm (placebo and statins and ezetimibe groups).
PCSK9 inhibitor effects on mortality were not recorded for the
ezetimibe and statin comparison, and were potentially neutral for
the placebo comparison; the latter may be related to the mod-
est follow-up time mentioned. Observed high heterogeneity in
biomarker response suggests that personalised PCSK9 treatment
regimens may be needed to optimise patient benefit.
Implications for research
Besides exploring the long-term effects of PCSK9 inhibition on
CVD-related endpoints, especially when compared against ac-
tive comparisons such as ezetimibe and statins, ongoing research
should explore potential safety issues. Given the magnitude of the
between-study heterogeneity discussed, future studies should ex-
plore (the need for) personalised medicine algorithms to ensure
that patients benefit optimally. Currenlty, no data have been ob-
tained on the comparison of PCSK9 inhibitors themselves; ideally,
these should be explored by a factorial RCT (instead of between
RCTs on the basis of network meta-analysis).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Ballantyne 2015
Methods Type of RCT: 5:2 parallel-group, double-blind dose-ranging RCTs
Settings: outpatient care
Duration: 24 weeks
Start and stop dates: 07/2012 and 05/2013
Participants Number of participants: 354
Number lost to follow-up:NA
Women: 182 (51%)
Age (SD), years: 59 (11)
History of CVD: NA
Participants with FH: NA
Participants with hypercholesterolaemia on stable statin therapy with fasting LDL-C of
80 mg/dL or more and triglycerides of 400 mg/dL or less
Interventions Background therapy: statin therapy
Randomised therapy: bococizumab (RN316) vs placebo
Bococizumab dose: Participants were offered 50 mg, 100 mg, 150 mg once every 2
weeks, or 200 mg, 300 mg every 4 weeks, resulting in a dosage range of 50 mg to 150
mg every 2 weeks
Intervention was continued for 24 weeks with dose reduction at day 43 (14-week regi-
men) or at day 57 (28-week regimen)
Outcomes Adverse events
Notes • Lipid measurement available for 12 weeks of follow-up
• NCT01592240
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation by interactive voice-re-
sponse system
Allocation concealment (selection bias) Unclear risk Unclear how the interactive voice system
was implemented
Blinding of participants and personnel
(performance bias)
LDL-C
Unclear risk Although paper and appendix describe the
study as double-blind, it is unclear how
this was maintained and who was blinded.
However, no LDL-C measurement was
available at/near any of the predefined time
points, making this less important
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Ballantyne 2015 (Continued)
Blinding of outcome assessment (detection
bias)
LDL-C
Low risk Although paper and appendix describe the
study as double-blind, it is unclear how this
was maintained and who was blinded. Any
lack of blinding of participants and person-
nel seems unlikely to bias LDL-C assess-
ment, which was performed in indepen-
dent laboratories. On the other hand, out-
comes such as adverse events may be biased
owing to detection bias
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not reported; mixed-effects models, in-
cluding baseline measurement, were used
for continuous outcomes
Selective reporting (reporting bias) Unclear risk Study protocol was unavailable
Other bias High risk Funded by Pfizer
Descartes
Methods Type of RCT: 2:1 parallel-group, double-blind RCT with stratified randomisation
Settings: outpatient care
Duration: 52 weeks
Start and stop dates: 01/2012 and 11/2013
Participants Number of participants: 905 (901 with baseline data)
Number lost to follow-up: 134
Women: 471 (52%)
Age (SD), years: 56 (11)
History of CVD: 136 (15%)
Participants with FH: NA
Participants with fasting LDL-C of 75 mg/dL or more and fasting triglyceride level of
400 mg/dL
Interventions Background therapy: standard of care, which consisted of diet only, daily atorvastatin
10 mg, 80 mg, or 80 mg + 10 mg ezetimibe
Randomised therapy: evolocumab every 4 weeks vs placebo
Evolocumab dose: 48 weeks of 420 mg each 4 weeks. Two-week equivalent dose of 210
mg
Outcomes CVD, lipids, any adverse events, all-cause mortality, glucose, HbA1c (change from base-
line)
Notes • All lipid analyses were performed by Medpace Reference Laboratories (MRL).
Laboratories maintained Part III certification according to the Centers for Disease
Control and Prevention (CDC) Lipid Standardization Program throughout the study
• Low-density lipoprotein cholesterol and very low-density lipoprotein cholesterol
were measured after preparative ultracentrifugation (β-quantification). Calculated low-
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Descartes (Continued)
density lipoprotein cholesterol was derived with the Friedewald formula
• Triglycerides and cholesterol were measured with enzymatic colorimetric tests
(Olympus AU2700 or AU5400 Analyzer, Olympus, Center Valley, PA) with
calibration directly traceable to CDC reference procedures
• ApoB-containing lipoproteins were precipitated with dextran sulfate, and high-
density lipoprotein cholesterol was measured in the supernatant. ApoA1 and ApoB
were measured with rate immunonephelometry (Dade Behring BNII nephelometer,
Siemens Healthcare Diagnostics, Deerfield, IL), and Lp(a) was measured by immuno
turbidimetry (Denka Seiken Co. Ltd. Lp(a) assay from Polymedco, Cortlandt Manor,
NY, on the Olympus Analyzer)
• NCT01516879
• Parent trial of OSLER-2
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation performed centrally using
an interactive voice-response system
Allocation concealment (selection bias) Low risk Randomisation performed centrally using
an interactive system
Blinding of participants and personnel
(performance bias)
LDL-C
Unclear risk Although paper and appendix describe the
study as double-blind, it is unclear how this
wasmaintained and whowas blinded. Lack
of blinding will likely cause a change in ad-
herence and/or participant choices regard-
ing SOC/lifestyle, which may influences
outcomes
Blinding of outcome assessment (detection
bias)
LDL-C
Low risk Although paper and appendix describe the
study as double-blind, it is unclear how
this was maintained and who was blinded.
However, any lack of blinding of partic-
ipants and personnel seems unlikely to
bias LDL-C assessment, which was per-
formed in independent laboratories. Out-
comes such as adverse events may be biased
owing to detection bias
Incomplete outcome data (attrition bias)
All outcomes
High risk 4 participants were randomised but were
not included in the ITT (small number,
good). However, at 2 weeks of follow-up,
the number of available patients had de-
creased by about 15% (number of miss-
ing measurements 44 (14.57%) in com-
parison arm, and 90 (15.03%) in interven-
tion arm). In some of these cases, miss-
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Descartes (Continued)
ing patients are likely due to different en-
rolment times, limiting follow-up; how-
ever, reported numbers of discontinued
participants were similarly high: 73 in the
evolocumab armand28 in the placebo arm.
Missing LDL-C data were imputed used
linear mixed models, including baseline
measurements. Other missing lipid mea-
surements were imputed using a last obser-
vation carried forward approach and were
analysed by ANCOVA
Selective reporting (reporting bias) Unclear risk Study protocol was unavailable
Other bias High risk Funded by Amgen
Equator
Methods Type of RCT: 1:3 parallel-group, double-blind dose-ranging RCT
Settings: outpatient care
Duration: 24 weeks
Start and stop dates: NA
Participants Number of participants: 248 (247 with baseline data)
Number lost to follow-up: 20
Women: 107 (43%)
Age (SD), years: 64 (8)
History of CVD: 129 (52%)
Participants with FH: NA
Participants with established CHD or CHD equivalent risk (not defined further)
Interventions Background therapy: standard of care, potentially including statin therapy
Randomised therapy: 24 weeks of RG7652 (MPSK3169A) every 4, 8, or 12 weeks vs
placebo
RUG7652 dose: 5 dosage regimens were administered: 200 mg every 8 weeks, 400 mg
every 8 weeks, 800 mg every 12 weeks, 400 mg every 4 weeks, 800 mg every 8 weeks,
resulting in a 2-week equivalent dose of 50 mg to 200 mg
Outcomes Lipids, any adverse events, CVD, all-cause mortality
Notes • Reduction in lipids was given as an overall P value and as a range of effects. Effect
was averaged and standard error was calculated assuming a standard normal
distribution. This results in a very conservative estimate of precision
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Equator (Continued)
Random sequence generation (selection
bias)
Unclear risk Only an abstract/poster was available
Allocation concealment (selection bias) Unclear risk Only an abstract/poster was available
Blinding of participants and personnel
(performance bias)
LDL-C
Unclear risk Only an abstract/poster was available
Blinding of outcome assessment (detection
bias)
LDL-C
Unclear risk Only an abstract/poster was available. Un-
known if a central laboratory was used
Incomplete outcome data (attrition bias)
All outcomes
High risk 1 participant was excluded from modified
ITT population, and 19 participants (7.
66%) did not complete the study
Selective reporting (reporting bias) Unclear risk Full paper has not yet been published
Other bias High risk Funded by F. Hoffman-La Roche Ltd
FOURIER
Methods Type of RCT: 1:1 parallel-group, double-blind RCT
Settings: outpatient care
Duration: 157 weeks (36 months)
Start and stop dates: 02/2013; 11/2016
Participants Number of participants: 27,564 (39 did not receive treatment)
Number lost to follow-up: 1558 participants had observed LDL-C measurements at
36 months, 1375 completed follow-up time of 36 months for the primary endpoint of
CVD
Women: 6769 (25%)
Age (SD), years: 63 (9)
History of CVD: 27,564 (100%), not reported but inferred on the basis of inclusion
criteria
Participants with FH: NA
Inclusion criteria
• Male or female ≥ 40 to ≤ 85 years of age
• History of clinically evident cardiovascular disease at high risk for a recurrent event
• Fasting LDL-C ≥ 70 mg/dL (≥ 1.8 mmol/L) ) or non-HDL-C ≥ 100 mg/dL (>
2.6 mmol/L)
• Fasting triglycerides ≤ 400 mg/dL (4.5 mmol/L)
Exclusion criteria
• NYHA class III or IV, or last known left ventricular ejection fraction < 30%
• Uncontrolled hypertension
• Uncontrolled or recurrent ventricular tachycardia
• Untreated hyperthyroidism or hypothyroidism
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FOURIER (Continued)
• Homozygous familial hypercholesterolaemia
• LDL or plasma apheresis
Interventions Background therapy: statin therapy.
Randomized therapy: evolocumab compared to placebo.
RUG7652 dose: 140 mg/2w or to 420 mg/4w of evolocumab. Resulting in a two week
equivalent dose of 140mg-210mg
Outcomes LDL-C, any adverse events, CVD, all-cause mortality, T2DM
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central computerized system
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
LDL-C
Low risk Both were blinded
Blinding of outcome assessment (detection
bias)
LDL-C
Low risk Central laboratory and blinded adjudica-
tion
Incomplete outcome data (attrition bias)
All outcomes
Low risk 27564 patients were randomized of whom
39didnot receive any treatment. The num-
ber of participants available reduced con-
siderably over time to only 1375 subjects re-
maining at study end.However, as reported
loss to follow-up was only 0.1% and the
decrease in number reflects different enrol-
ment times
Selective reporting (reporting bias) Low risk Reports on most endpoints
Other bias High risk Amgen
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ODYSSEY CHOICE II
Methods Type of RCT: 1:2 parallel group, double-blind RCT.
Settings: outpatient care.
Duration: 24 weeks
Start and stop dates: 12/2013; 06/2017
Participants Number of participants: 233
Number lost to follow-up:NA
Women: 103 (44%)
Age(SD): 63 (10)
History of CVD: NA
FH participants: 29 (12%)
Participants with primary hypercholesterolaemia (heFH or non-FH) with high CV risk
with muscle related statin intolerance, or moderate CV risk without muscle related statin
intolerance
Interventions Background therapy: ezetimibe, fenofibrate or diet alone.
Randomized therapy: alirocumab versus placebo.
Alirocumab dose: 24 weeks of 75 mg alirocumab every 2 weeks or 150 mg Alirocumab
every 4 weeks. At 12 weeks participants could switch to 150 mg every 2 weeks. Resulting
in a two week equivalent dose of 75-150mg
Outcomes lipids, any adverse events, all-cause mortality.
Notes • All results based on an abstract.
• Results presented as Alirocumab versus placebo.
• NCT0203879
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported.
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
LDL-C
Unclear risk Described as double-blind however no de-
tails are provided on who was blinded.
However, taking account of the other
Odyssey trials seems likely both patients
and personal were blinded
Blinding of outcome assessment (detection
bias)
LDL-C
Low risk No details are provided. However, LDL-C
and other biomarkers are unlikely biased
by any lack of blinded assessment. Further-
more, all otherOdyssey trails implemented
blinded assessment
46PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
ODYSSEY CHOICE II (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No details are provided on missing data.
Selective reporting (reporting bias) Unclear risk The full paper has not yet been published.
Other bias High risk Funded by Sanofi and Regeneron.
ODYSSEY ALTERNATIVE
Methods Type of RCT: 1:1 parallel-group RCT, with stratification for CVD history
Settings: outpatient care
Duration: 24 weeks
Start and stop dates: 09/2012 and 09/2016
Participants Number of participants: 251 (excluding 63 participants in an atorvastatin rechallenge
arm)
Number lost to follow-up: 80
Women: 114 (45%)
Age (SD), years: 63 (10)
History of CVD: 115 (46%)
FH participants: 38 (15%)
Participants with primary hypercholesterolaemia and moderate, high, or very high CV
risk, who are intolerant to statins
377 participants with a history of statin intolerance, and of moderate, high, or very
high CV risk. Moderate CV risk defined as SCORE risk of 1% or more but lower
than 5%; high risk defined as score risk of 5% or more, or moderate chronic kidney
disease, diabetes without target organ damage heFH; very high risk defined as history of
documented CHD, ischaemic stroke, peripheral artery disease, TIA, abdominal aortic
aneurysm, or carotid artery stent procedure, or carotid endarterectomy or carotid artery
stent procedure, or renal artery stenosis or renal artery stent procedure or diabetes with
target organ damage
Interventions Background therapy:National Cholesterol Education Program Adult Treatment Panel
III therapeutic lifestyle changes diet. Participants were allowed to continue to use bile
acid, nicotinic acid, fenofibrate, or mega-3 acid
Randomised therapy: alirocumab and placebo vs daily 10 mg ezetimibe or 20 mg
atorvastatin and placebo
Alirocumab dose: 24 weeks 75 mg alirocumab every 2 weeks, with uptitration of
alirocumab to 150 mg every 2 weeks at week 12. Resulting in a 2-week equivalent dose
of 75 mg to 150 mg
Outcomes MACE, lipids, any adverse events, all-cause mortality
Notes • Atorvastatin arm was included as a re-challenge experiment. Main analysis focuses
on alirocumab vs ezetimibe (151 participants)
• LDL-C was calculated using the Friedewald formula
• NCT01709513
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ODYSSEY ALTERNATIVE (Continued)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Low risk Permuted-block design and central alloca-
tion
Blinding of participants and personnel
(performance bias)
LDL-C
Low risk Placebo-controlled, patients self-adminis-
tered. Unclear if staff was also blinded. Any
potential unblinding of staff would be un-
likely to result in bias in association with
biomarkers
Blinding of outcome assessment (detection
bias)
LDL-C
Low risk Lipid parameters assessed at central blinded
laboratory
Incomplete outcome data (attrition bias)
All outcomes
High risk 36 (28.6%) participants in the alirocumab
arm had missing lipid measurements com-
pared with 44 (36.1%) in the ezetimibe
arm. Potenially, these “missing” partici-
pants simply did not make the required fol-
low-up time (24 weeks) owing to late en-
rolment; without specific description of the
reason for these lower numbers, some con-
cern is warranted
Selective reporting (reporting bias) Unclear risk Full paper has not yet been published
Other bias High risk Funded by Sanofi and Regeneron
ODYSSEY CHOICE I
Methods Type of RCT: 1:2 parallel-group, double-blind, stratified RCT
Settings: outpatient care.
Duration: 24 weeks
Start and stop dates: 10/2013 and 05/2015
Participants Number of participants: 803
Number lost to follow-up:NA
Women: 341 (42%)
Age (SD), years: 60 (10)
History of CVD: NA
Participants with FH: 45 (6%)
Participants with poorly controlled hypercholesterolaemia and moderate CV risk with
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ODYSSEY CHOICE I (Continued)
or without muscle-related statin intolerance, or with high CV risk receiving maximally
tolerated dose.Nodefinition of poorly controlled ormoderate/highCV riskwas provided
Interventions Background therapy: statin therapy.
Randomized therapy: alirocumab vs placebo. At 12 weeks, participants could switch to
150 mg every 2 weeks
Alirocumab dose: 48 weeks 75 mg alirocumab every 2 weeks or 300 mg alirocumab
every 4 weeks. Resulting in a 2-week equivalent dose of 75 mg to 150 mg. Treatment
was allocated stratified on statin use or not
Outcomes Lipids, any adverse events, all-cause mortality
Notes • All results based on an abstract
• Results presented as alirocumab vs placebo
• NCT01926782
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
LDL-C
Unclear risk Described as double-blind, but no details
provided on who was blinded. However,
taking account of the other Odyssey trials,
seems likely both participants and personal
were blinded
Blinding of outcome assessment (detection
bias)
LDL-C
Low risk No details are provided. However, LDL-C
and other biomarkers are unlikely biased
by any lack of blinded assessment. Further-
more, all otherOdyssey trials implemented
blinded assessment using a central labora-
tory
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No details of missing data are provided
Selective reporting (reporting bias) Unclear risk Full paper has not yet been published
Other bias High risk Funded by Sanofi and Regeneron
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ODYSSEY COMBO I
Methods Type of RCT: 1:2 parallel-group, double-blind, stratified RCT
Settings: outpatient care
Duration: 52 weeks
Start and stop dates: 07/2012 and 04/2014
Participants Number of participants: 316
Number lost to follow-up: 30
Women: 108 (34%)
Age (SD), years: 63 (9)
History of CVD: 247 (78%)
FH participants: 0
Participants with hypercholesterolaemia (LDL-C ≥ 70 mg/dL) and established CVD
or LDL-C of 100 mg/dL and CHD risk equivalents (e.g. chronic kidney disease) and
on a maximally tolerated dose of statin, with possible addition of other lipid-lowering
therapies
Interventions Background therapy: both add-on to maximal tolerated dose of statin
Randomised therapy: alirocumab vs placebo
Alirocumab dose: 104 weeks of 75 mg alirocumab every 2 weeks, with uptitration of
alirocumab to 150 mg every 2 weeks at week 12. resulting in a 2-week equivalent dose
of 75 mg to 150 mg
Outcomes CVD, lipids, any adverse events, all-cause mortality
Notes • LDL-C was calculated using the Friedewald formula, or if triglycerides exceeded
400 mg/dL, via the beta quantification method
• NCT01644175
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Does not mention randomisation but pre-
sumably similar as COMBO II: using an
interactive voice-response system
Allocation concealment (selection bias) Unclear risk Does not describe this
Blinding of participants and personnel
(performance bias)
LDL-C
Low risk Both were blinded
Blinding of outcome assessment (detection
bias)
LDL-C
Low risk Central laboratory
Incomplete outcome data (attrition bias)
All outcomes
High risk 20 (9.57%) participants in the alirocumab
arm had missing lipid measurements com-
pared with 10 (9.34%) in the compara-
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ODYSSEY COMBO I (Continued)
tor arm. Potenially, these “missing” partici-
pants simply did not make the required fol-
low-up time (24 weeks) owing to late en-
rolment; however, without specific descrip-
tion of the reasons for these lower numbers,
some concern is warranted
Selective reporting (reporting bias) Low risk Reports on protocol-defined endpoints
Other bias High risk Funded by Sanofi and Regeneron
ODYSSEY COMBO II
Methods Type of RCT: 2:1 parallel-group, double-blind, stratified, permuted-block RCT
Settings: outpatient care
Duration: 104 weeks
Start and stop dates: 08/2012 and 07/2015
Participants Number of participants: 720
Number lost to follow-up: 13
Women: 190 (26%)
Age (SD), years: 62 (9)
History of CVD: 649 (90%)
FH participants: 0
Participants with hypercholesterolaemia (not defined) and established CHD or CHD
risk equivalents (Ischaemic stroke, peripheral artery disease, moderate chronic kidney
disease, or diabetes mellitus plus 2 or more additional risk factors) and on a maximally
tolerated dose of statin, without addition of other lipid-lowering therapies
Interventions Background therapy: add-on to maximal tolerated dose of statin
Randomised therapy: alirocumab and ezetimibe placebo vs 10 mg daily of ezetimibe
and placebo
Alirocumab: 104 weeks of 75 mg alirocumab every 2 weeks, with uptitration of
alirocumab to 150 mg every 2 weeks at week 12, resulting in a 2-week equivalent dose
of 75 mg to 150 mg
Outcomes CVD, lipids, any adverse events, all-cause mortality
Notes • LDL-C was calculated using the Friedewald formula, or if triglycerides exceeded
400 mg/dL, via the beta quantification method
• NCT01644188
• Still ongoing, results are for 52 weeks
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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ODYSSEY COMBO II (Continued)
Random sequence generation (selection
bias)
Low risk Using an interactive voice-response system
Allocation concealment (selection bias) Low risk Permuted blocks
Blinding of participants and personnel
(performance bias)
LDL-C
Low risk Both were blinded
Blinding of outcome assessment (detection
bias)
LDL-C
Low risk Central laboratory
Incomplete outcome data (attrition bias)
All outcomes
Low risk 12 (2.51%) participants in the alirocumab
arm had missing lipid measurements com-
pared with 1 (0.41) in the compara-
tor arm. Additionally, mixed-effects (AN-
COVA) models were used
Selective reporting (reporting bias) Low risk Reports on protocol-defined endpoints
Other bias High risk Funded by Sanofi and Regeneron
ODYSSEY FH I
Methods Type of RCT: 2:1 parallel-group, double-blind, stratified RCT
Settings: outpatient care
Duration: 78 weeks
Start and stop dates: 07/2012; 12/2014
Participants Number of participants: 486
Number lost to follow-up: 1
Women: 212 (44%)
Age (SD), years: 52 (13)
History of CVD: 225 (46%)
Participants with FH: 485 (100%)
Participants with heterozygous familial hypercholesterolaemia on a maximally tolerated
dose of statin with LDL-C of 70 mg/dL or higher or 100 mg/dL or higher, depending
on CV risk
Interventions Background therapy: add-on to maximal tolerated dose of statin and possible addition
of other lipid-lowering therapies
Randomized therapy: alirocumab vs placebo
Alirocumab dose: 78weeks of 75mg alirocumab every 2weeks, with possible uptitration
of alirocumab to 150 mg every 2 weeks at week 12. Resulting in a 2-week equivalent
dose of 75 mg to 150 mg
Outcomes CVD, lipids, any adverse events, all-cause mortality
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ODYSSEY FH I (Continued)
Notes • LDL-C was calculated using the Friedewald formula, or if triglycerides exceeded
400 mg/dL, via the beta quantification method
• NCT01623155
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Centralised interactive voice-response sys-
tem or interactive Web-response system
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
LDL-C
Low risk Both were blinded
Blinding of outcome assessment (detection
bias)
LDL-C
Low risk Central laboratory
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1 (0.31%) participant in the alirocumab
arm had missing lipid measurements com-
pared with 0 in the comparator arm. Addi-
tionally, mixed-effects (ANCOVA) models
were used
Selective reporting (reporting bias) Low risk Reports on protocol-defined endpoints
Other bias High risk Funded by Sanofi and Regeneron
ODYSSEY FH II
Methods Type of RCT: 2:1 parallel-group, double-blind, stratified RCT
Settings: outpatient care
Duration: 52 weeks
Start and stop dates: 12/2012 and 01/2015
Participants Number of participants: 249
Number lost to follow-up: 2
Women: 118 (47%)
Age (SD), years: 53.2 (17.2)
History of CVD: 89 (36%)
Participants with FH: 249 (100%)
Participants with heFH not adequately controlled with a maximally tolerated daily dose
of statin with or without the other LMT, at a stable dose before the screening visit
53PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
ODYSSEY FH II (Continued)
Interventions Background therapy: add-on to maximal tolerated dose of statin and possible addition
of other lipid-lowering therapies
Randomised therapy: alirocumab vs placebo
Alirocumab dose: 78 weeks 75 mg alirocumab every 2 weeks, with possible uptitration
of alirocumab to 150 mg every 2 weeks at week 12. Resulting in a 2-week equivalent
dose of 75 mg to 150 mg
Outcomes CVD, lipids, any adverse events, all-cause mortality
Notes • LDL-C was calculated using the Friedewald formula, or if triglycerides exceeded
400 mg/dL, via the beta quantification method
• NCT01709500
• Subgroup analyses are provided for FH I and FH II combined
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Centralised interactive voice-response sys-
tem or interactive Web-response system
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
LDL-C
Low risk Both were blinded
Blinding of outcome assessment (detection
bias)
LDL-C
Low risk Central laboratory
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1 (0.60%) portion of the alirocumab arm
had missing lipid measurements compared
with 1 (1.22%) participant in the compara-
tor arm. Additionally, mixed-effects (AN-
COVA) models were used
Selective reporting (reporting bias) Low risk Reports on protocol-defined endpoints
Other bias High risk Funded by Sanofi and Regeneron
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ODYSSEY HIGH FH
Methods Type of RCT: 2:1 parallel-group, double-blind, stratified RCT
Settings: outpatient care
Duration: 78 weeks
Start and stop dates: 12/2012 and 01/2015
Participants Number of participants: 107
Number lost to follow-up: 1
Women: NA
Age (SD), years: NA
History of CVD: 64 (60%)
Participants with FH: 107 (100%)
Participants with heterozygous familial hypercholesterolaemia on a maximally tolerated
dose of statin with LDL-C ≥ 160 mg/dL
Interventions Background therapy: both add-on to maximal tolerated dose of statin and possible
addition of other lipid-lowering therapies
Randomized therapy: alirocumab vs placebo
Alirocumab dose: 78 weeks of 150 mg alirocumab every 2 weeks
Outcomes CVD, lipids, any adverse events, all-cause mortality
Notes • LDL-C was calculated using the Friedewald formula
• Reports on influenza
• Subgroup analyses are provided for FH I and FH II combined
• NCT01617655
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Centralised interactive voice-response sys-
tem or interactive Web-response system
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
LDL-C
Low risk Both were blinded
Blinding of outcome assessment (detection
bias)
LDL-C
Low risk Central laboratory
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1 (1.38%) participant in the alirocumab
arm had missing lipid measurements com-
pared with 0 in the comparator arm. Addi-
tionally, mixed-effects (ANCOVA) models
were used
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ODYSSEY HIGH FH (Continued)
Selective reporting (reporting bias) Unclear risk Full paper has not yet been published
Other bias High risk Funded by Sanofi and Regeneron
ODYSSEY Long Term
Methods Type of RCT: 2:1 parallel-group, double-blind RCT with stratified randomisation
Settings: outpatient care
Duration: 78 weeks
Start and stop dates: 01/2012 and 11/2014
Participants Number of participants: 2341
Number lost to follow-up: 247
Women: 884 (38%)
Age (SD), years: 63 (11)
History of CVD: 1607 (68%)
Participants with FH: 415 (18%)
Participants with heterozygous familial hypercholesterolaemia or established coronary
heart disease or coronary heart disease risk equivalent
Interventions Background therapy: standard of care
Randomized therapy: alirocumab vs placebo for 78 weeks
Alirocumab dose: 150 mg alirocumab every 2 weeks
Outcomes CVD, lipids, any adverse events, all-cause mortality
Notes • Blood samples were obtained after a 10-hour overnight fast
• Total cholesterol, triglycerides, and HDL cholesterol levels in serum were
determined via Centers for Disease Control and Prevention, National Heart Lung
Blood Institute Lipid Standardization Program assays
• LDL cholesterol was calculated using the Friedewald formula at all sampling
points. LDL cholesterol was also measured via ultracentrifugation and precipitation
(beta-quantification) by the central laboratory at weeks 0, 12, 24, 52, and 78, and in
cases where triglyceride values were > 400 mg per decilitre
• Apolipoprotein B, apolipoprotein A1, and lipoprotein(a) levels in serum were
determined via immunonephelometry
• NCT01507831
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central computer-generated allocation sys-
tem
Allocation concealment (selection bias) Low risk Central computer-generated allocation sys-
tem
56PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
ODYSSEY Long Term (Continued)
Blinding of participants and personnel
(performance bias)
LDL-C
Low risk Participants and investigators were blinded
with placebo identically packaged as
alirocumab
Blinding of outcome assessment (detection
bias)
LDL-C
Low risk Biomarkers were assessed at a central labo-
ratory blinded for allocation. Clinical end-
points and adverse advents were similarly
assessed in a blinded fashion
Incomplete outcome data (attrition bias)
All outcomes
High risk ITT analysis excludes participants (167
(10.8%) in the intervention arm and
80 (10.1%) in the control arm) who
missed LDL-C measurements during first
24 weeks. In total, 437 alirocumab patients
did not complete study follow-up com-
pared with 193 placebo participants. Cat-
egorical outcomes were analysed using an
available case analysis. Missing biomarker
values were imputed using mixed models
or multiple imputations
Selective reporting (reporting bias) Low risk Reports on protocol-defined endpoints
Other bias High risk Funded by Sanofi and Regeneron
ODYSSEY MONO
Methods Type of RCT: 1:1 1:1 parallel-group, double-blind RCT
Settings: outpatient care
Duration: 24 weeks
Start and stop dates: 07/2012 and 07/2013
Participants Number of participants: 103
Number lost to follow-up: 0
Women: 48 (47%)
Age (SD), years: 60 (5)
History of CVD: 103 (100%)
Participants with FH: 0
Participants with 10-year risk of fatal CV events between 1% and < 5%
Interventions Background therapy:National Cholesterol Education Program Adult Treatment Panel
III therapeutic lifestyle changes diet
Randomized therapy: alirocumab and placebo ezetimibe daily vs 10 mg ezetimibe daily
plus alirocumab biweekly placebo
Alirocumab dose: 24 weeks 75 mg alirocumab every 2 weeks, at 12 weeks LDL-C
dependent uptitration of alirocumab occurred to 150 mg biweekly. Resulting in a 2-
week equivalent dose of 75 mg to 150 mg
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ODYSSEY MONO (Continued)
Outcomes CVD, lipids, any adverse events
Notes · LDL-C was calculated using the Friedewald formula
· NCT01644474
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Low risk Permuted-block design
Blinding of participants and personnel
(performance bias)
LDL-C
Low risk Participants were blinded for treatment al-
location and self-administered treatments
Blinding of outcome assessment (detection
bias)
LDL-C
Low risk Central laboratory
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants were available at 24 weeks
of follow-up
Selective reporting (reporting bias) Low risk Reports on protocol-defined endpoints
Other bias High risk Funded by Sanofi and Regeneron
ODYSSEY OPTIONS I
Methods Type of RCT: 2:1 parallel-group, double-blind, stratified, permuted-block designed
RCT
Settings: outpatient care
Duration: 24 weeks
Start and stop dates: NA
Participants Number of participants: 355
Number lost to follow-up: 10
Women: 124 (35%)
Age (SD), years: 63 (10)
History of CVD: 200 (56%)
FH participants: 31 (9%)
Participants with history of CVD and LDL-C levels ≥ 70 mg/dL, or CVD risk factors
and LDL-C ≥ 100 mg/dL
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ODYSSEY OPTIONS I (Continued)
Interventions Background therapy: 24 weeks 20 or 40 mg of baseline atorvastatin and National
Cholesterol Education Program Adult Treatment Panel III
Randomised therapy: alirocumab versus 10 mg ezetimibe per day, or 20 or 40 mg
atorvastatin, or for atorvastatin 40 mg regimen only, switch to rosuvastatin
40 mg
Alirocumab dose: 75 mg alirocumab every 2 weeks, with uptitration of alirocumab to
150 mg at week 12. Resulting in a 2-week equivalent dose of 75 mg to 150 mg
Resulting in 7 groups
• 20 mg atorvastatin plus 75 mg alirocumab every 2 weeks
• 20 mg atorvastatin plus 10 mg ezetimibe every day
• 20 mg atorvastatin plus 20 mg atorvastatin every day
• 40 mg atorvastatin plus 75 mg alirocumab every 2 weeks
• 40 mg atorvastatin plus 10 mg ezetimibe every day
• 40 mg atorvastatin plus 40 mg atorvastatin every day
• 40 mg of rosuvastatin
All blinded with placebo alirocumab and over-encapsulated tables for ezetimibe, ator-
vastatin, and rosuvastatin
Outcomes CVD, lipids, any adverse events, all-cause mortality
Notes • Unless otherwise specified, comparisons are made of alirocumab therapy vs
pooled other therapies
• Fasting blood samples were collected in the morning
• LDL-C was calculated using the Friedewald formula
• Lipoprotein(a) was analysed using an immunoradiometric assay on the Siemens
BNII
• NCT01730040
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Centralised interactive voice-response sys-
tem or interactive Web-response system
Allocation concealment (selection bias) Low risk Permuted-block design and central alloca-
tion
Blinding of participants and personnel
(performance bias)
LDL-C
Low risk Both were blinded
Blinding of outcome assessment (detection
bias)
LDL-C
Low risk Central laboratory
Incomplete outcome data (attrition bias)
All outcomes
Low risk 4 (3.85%) participants in the alirocumab
arm hadmissing lipids measurements com-
pared with 6 (2.39%) in the compara-
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ODYSSEY OPTIONS I (Continued)
tor arm. Additionally, mixed-effects (AN-
COVA) models were used
Selective reporting (reporting bias) Low risk Reports on protocol-defined endpoints
Other bias High risk Funded by Sanofi and Regeneron
ODYSSEY OPTIONS II
Methods Type of RCT: double-blind, placebo-controlled, parallel-group RCT
Settings: outpatient care
Duration: 24 weeks
Start and stop dates: NA
Participants Number of participants: 305
Number lost to follow-up: 7
Women: 118 (39%)
Age (SD), years: 61 (10)
History of CVD: 177 (58%)
Participants with FH: 41 (13%)
Participants with a history of CVD and LDL-C levels≥ 70 mg/dL, or CVD risk factors
and LDL-C ≥ 100 mg/dL
Interventions Background therapy: Patients received 24 weeks 10 or 20 mg of baseline rosuvastatin
and National Cholesterol Education Program Adult Treatment Panel III
Randomised therapy: alirocumab vs add-on 10 mg ezetimibe per day, or additional 10
or 20 mg of rosuvastatin
Alirocumab dose: add-on of 75 mg alirocumab every 2 weeks, with uptitration of
alirocumab to 150 mg at week 12. Resulting in a 2-week equivalent dose of 75 mg to
150 mg
Resulting in 6 groups
• 10 mg rosuvastatin plus 75 mg alirocumab every 2 weeks
• 10 mg rosuvastatin plus 10 mg ezetimibe every day
• 10 mg rosuvastatin plus 10 mg rosuvastatin every day
• 20 mg rosuvastatin plus 75 mg alirocumab every 2 weeks
• 20 mg rosuvastatin plus 10 mg ezetimibe every day
• 20 mg rosuvastatin plus 20 mg rosuvastatin every day
All blinded with placebo alirocumab and over-encapsulated tables for ezetimibe, rosu-
vastatin
Outcomes CVD, lipids, any adverse events, all-cause mortality
Notes • Unless otherwise specified, comparisons are made of alirocumab therapy vs
pooled other therapies
• Fasting blood samples were collected in the morning
• LDL-C was calculated using the Friedewald formula
• Lipoprotein(a) was analysed using an immunoradiometric assay on the Siemens
BNII
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ODYSSEY OPTIONS II (Continued)
• NCT01730053
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Centralised interactive voice-response sys-
tem or interactive Web-response system
Allocation concealment (selection bias) Low risk Permuted-block design and central alloca-
tion
Blinding of participants and personnel
(performance bias)
LDL-C
Low risk Both were blinded
Blinding of outcome assessment (detection
bias)
LDL-C
Low risk Central laboratory
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2 (1.94%) participants in the alirocumab
arm had missing lipid measurements com-
pared with 5 (2.48%) in the compara-
tor arms. Additionally, mixed-effects (AN-
COVA) models were used
Selective reporting (reporting bias) Low risk Reports on protocol-defined endpoints
Other bias High risk Funded by Sanofi and Regeneron
OSLER 1/2
Methods Type of RCT: meta-analysis of OSLER-1 and OSLER-2 RCTs
Settings: outpatient care
Duration: 52 weeks/48 weeks
Start and stop dates: NA
Participants Number of participants: 4465
Number lost to follow-up: 738
Women: 2210 (49%)
Age (SD), years: 58 (11)
History of CVD: NA
Participants with FH: NA
Participants with and without a history of CVD or familial hypercholesterolaemia; all
were previously enrolled in phase 2 to 3 PCSK9 inhibitor trials and completed these
without serious adverse events
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OSLER 1/2 (Continued)
Interventions Background therapy: standard of care (including statins and/or ezetimibe).
Randomised therapy: evolocumab vs standard of care only, for 52/48 weeks
Evolocumab dose: 420 mg evolocumab every 4 weeks (OSLER-1, OSLER-2), or 140
mg every 2 weeks (OSLER-2), resulting in 2-week equivalent dose of 140 mg to 210 mg
Outcomes CVD, LDL-C, any adverse events, all-cause mortality
Notes • DESCARTES leads into OSLER-2
• Standard error for LDL-C percentage changes unavailable at 48 weeks; instead,
standard error of 24 weeks was used
• Blood samples were obtained after a 9-hour or longer overnight fast
• LDL cholesterol was calculated using the Friedewald formula at all sampling
points
• NCT01439880, NCT01439880
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was performed centrally
with the use of an interactive voice-re-
sponse or Web-response system
Allocation concealment (selection bias) Low risk Central allocation
Blinding of participants and personnel
(performance bias)
LDL-C
High risk No blinding; lack of blinding will likely
cause a change in adherence and/or in a par-
ticipant’s choices regarding SOC/lifestyle
that may influences outcomes
Blinding of outcome assessment (detection
bias)
LDL-C
Low risk Central laboratory. Outcomes directly as-
sessed by study personnel, such as adverse
events, may be biased owing to detection
bias
Incomplete outcome data (attrition bias)
All outcomes
High risk At week 48, 270 (18.13%) SOC partici-
pants were unavailable, and 468 (15.72%)
in the intervention arm were unavailable.
Portion of these “unavailable” participants
were due to differences in enrolment dates
limiting follow-up, but with a reported per-
centage of 7.2%, a considerable proportion
of participants were genuinely lost to fol-
low-up. No mention of how missing data
were handled
Selective reporting (reporting bias) Low risk Reports on protocol-defined endpoints
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OSLER 1/2 (Continued)
Other bias High risk Analyses such as the Wilcoxon test, or Cox
proportional hazards model without strati-
fication for centre, ignore clustering of par-
ticipants by studies or by study centres
Funded by Amgen
OSLER-1
Methods Type of RCT: 1:2 parallel-group, open-label stratified trial
Settings: outpatient care
Duration: 52 weeks
Start and stop dates: NA
Participants Number of participants: 1104
Number lost to follow-up: 169
Women: 610 (55%)
Age (SD), years: 56 (12)
History of CVD: 210 (19%)
FH participants: 414 (38%)
Participants with and without a history of CVD or familial hypercholesterolaemia; all
were previously enrolled in phase 2 PCSK9 inhibitor trials and completed these trials
without serious adverse events
Interventions Background therapy: standard of care (SOC)
Randomized therapy: evolocumab vs standard of care for 52 weeks
Evolocumab dose: 420 mg evolocumab every 4 weeks, resulting in a 2-week equivalent
dose of 210 mg
Outcomes CVD, lipids, any adverse events, all-cause mortality
Notes • Plasma lipids, ApoA1, ApoB, and lipoprotein(a) were measured after a fast ≥ 9
hours
• LDL-C values are based on the preparative ultracentrifugation method
• Lipoprotein(a) assay type: Polymedco Cortlandt Manor, NY, on the Olympus
Analyzer
• NCT01439880
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was performed centrally
with the use of an interactive voice-re-
sponse or Web-response system
Allocation concealment (selection bias) Low risk Central allocation
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OSLER-1 (Continued)
Blinding of participants and personnel
(performance bias)
LDL-C
High risk No blinding. Lack of blinding will likely
cause a change in adherence and/or in par-
ticipants regarding SOC/lifestyle that may
influences outcomes
Blinding of outcome assessment (detection
bias)
LDL-C
Low risk Central laboratory. Besides lipids, out-
comes such as adverse events may be biased
owing to detection bias
Incomplete outcome data (attrition bias)
All outcomes
High risk At week 52, 73/368 = 19.83% of SOC
dropped out, and 96/736 = 13.04% of in-
tervention arm dropped out. No mention
of how missing data were handled
Selective reporting (reporting bias) Low risk Reports on protocol-defined endpoints
Other bias High risk Funded by Amgen
SPIRE 1/2
Methods Type of RCT: 1:1 parallel-group RCTs, double-blind, permuted-block design stratified
by geographic region
Settings: outpatient care
Duration: 143 weeks
Start and stop dates: both 10/2013 and 01/2017
Participants Number of participants: 27438 (39 participants did not receive treatment)
Number lost to follow-up: At week 52, the number of participants available for
biomarker measurements could be as low as 7814. For clinical endpoints, only 11 par-
ticipants made it to the end of follow-up (143 weeks), but this is likely to happen with
participants starting at different times and early termination of trials due to an antidrug-
antibody response
Women: 8111 (30%)
Age (SD), years: 63 (9)
History of CVD: 23198 (85%)
Participants with FH: 1072 (4%)
Inclusion criteria
• Must be on background lipid-lowering treatment
• Must be at high risk of a CV event
• Must have an LDL-C ≥ 100 mg/dL (2.6 mmol/L) OR non-HDL-C ≥ 130 mg/
dL (3.4 mmol/L)
Exclusion criteria
• Planned coronary (PCI or CABG) or other arterial revascularisation
• New York Heart Association Class IV congestive heart failure or left ventricular
ejection fraction < 25% by cardiac imaging
• Chronic renal insufficiency with creatinine clearance < 30 mL/min/1.73m2 by
MDRD formula or with end-state renal disease on dialysis
• History of haemorrhagic stroke
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SPIRE 1/2 (Continued)
• Prior exposure to bococizumab or other investigational PCSK9 inhibitor
Interventions Background therapy: statins and/or ezetimibe
Randomized therapy: bococizumab compared with placebo
Evolocumab dose: 150 mg/2w downtitration to 75 mg/2w
Outcomes CVD, lipids, any adverse events, all-cause mortality
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Interactive Response Technology (IRT)
System (Interactive Web Response (IWR)/
Interactive Voice Response (IVR) system)
Allocation concealment (selection bias) Low risk Permuted blocks
Blinding of participants and personnel
(performance bias)
LDL-C
Low risk Both were blinded
Blinding of outcome assessment (detection
bias)
LDL-C
Low risk Central laboratory andblinded adjudicated
clinical outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk Number of available participants at 52
weeks could be as low as 7814, depending
on the biomarker measured in a total of 27,
438 randomised participants. For clinical
endpoints, only 11 participants made it to
the end of follow-up (143 weeks). Both of
these issues are related to early termination
of these trials and participants enrolling at
different moments in time; actual loss to
follow-up was 0.9%
Selective reporting (reporting bias) Low risk Reports on most endpoints
Other bias High risk Pfizer funded
ANCOVA: analysis of covariance
CABG: coronary artery bypass graft
CHD: coronary heart disease
CV: cardiovascular
CVD: cardiovascular disease
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FH: familial hypercholesterolaemia
HbA1c: glycosylated haemoglobin
HDL-C: high-density lipoprotein cholesterol
heFH: heterozygous familial hypercholesterolaemia
ITT: intention-to-treat
LDL-C: low-density lipoprotein cholesterol
LMT: lipid modifying treatments
MACE: major adverse cardiac events
MDRD: Modification of Diet in Renal Disease
NYHA: New York Heart Association
PCI: percutaneous coronary intervention
RCT: randomised controlled trial
SD: standard deviation
SOC: standard of care
TIA: transient ischaemic attack
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Baruch 2013 Follow-up time too short
Cho 2014 Follow-up time too short
Desai 2014 Follow-up time too short
Dias 2012 Follow-up time too short
Dufour 2012 Meta-analysis without separate results
Gaudet 2012 Meta-analysis of 3 studies without separate results
Gaudet 2013 Meta-analysis of 3 studies without separate results
Gumbiner 2012 Follow-up time too short
Hopkins 2013 Follow-up time too short
Jones 2015 Meta-analysis of 4 studies without separate results
Kastelein 2015 Follow-up time too short
Kawashiri 2012 No randomisation to PCSK9 inhibitor
Mabuchi 2015 No empirical results
Maxwell 2012 No empirical results
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(Continued)
Mearns 2014 No empirical results
Pordy 2013 Dose-response modelling
Raal 2014 Follow-up time too short
Raal 2014a Meta-analysis without separate results
Shaywitz 2012 Follow-up time too short
Stawowy 2014 Follow-up time too short
Stein 2012 This reference published on a subset of the data included in OSLER-1
Stein 2013 Follow-up time too short
Swergold 2010 Follow-up time too short
Swergold 2011 Follow-up time too short
Wan 2013 Follow-up time too short
Characteristics of studies awaiting assessment [ordered by study ID]
SPIRE biomarker trials
Methods Six parallel, multi-national lipid-lowering trials
Participants 4300 patients with hyperlipidaemia
Interventions 150 mg bococizumab or placebo subcutaneously every 2 weeks
Outcomes Lipids, any adverse events, clinical endpoints
Notes Given the short follow-up time, the focus on biomarkers, and the fact that drug development has been terminated,
incorporation of these trials will have limited impact
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Characteristics of ongoing studies [ordered by study ID]
ANITSCHKOW
Trial name or title ANITSCHKOW
Methods Parallel randomised controlled trials
Participants People 50 to 80 years of age with baseline Lp(a) ≥ 50 mg/dL and LDL-C ≥ 100 mg/dL
Interventions Evolocumab compared with placebo with background statin therapy for all
Outcomes Number of participants with treatment-related adverse events as assessed by Common Terminology Criteria
for Adverse Events version 4
Starting date April 2016
Contact information
Notes Amgen
EBBINGHAUS
Trial name or title EBBINGHAUS
Methods Parallel randomised controlled trials
Participants People 40 to 85 years of age
Inclusion criteria
• Randomised into Study 20110118 (FOURIER)
Exclusion criteria
• Current or known past diagnosis of dementia or mild cognitive impairment (MCI)
Interventions Evolocumab compared with statin therapy in combination with placebo
Outcomes Mean change from baseline over time in spatial working memory (SWM) index of executive function
Starting date July 2014
Contact information
Notes Amgen, substudy of FOURIER
HAUSER-RCT
Trial name or title HAUSER-RCT
Methods Parallel randomised controlled trials
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HAUSER-RCT (Continued)
Participants Inclusion criteria
• Male or female ≥ 10 to ≤ 17 years of age (before 18th birthday)
• Diagnosis of heterozygous familial hypercholesterolaemia
• On an approved statin with stable optimised dose for ≥ 4 weeks
• Other lipid-lowering therapy stable for ≥ 4 weeks (fibrates must be stable for ≥ 6 weeks)
• Fasting LDL-C ≥ 130 mg/dL (3.4 mmol/L)
• Fasting triglycerides ≤ 400 mg/dL (4.5 mmol/L)
Exclusion criteria
• Type 1 diabetes, or type 2 diabetes that is poorly controlled
• Uncontrolled hyperthyroidism or hypothyroidism
• Cholesterylester transfer protein (CETP) inhibitor in the previous 12 months, or mipomersen or
lomitapide in the previous 5 months
• Previously received evolocumab or any other investigational therapy to inhibit PCSK9
• Lipid apheresis within the 12 weeks before screening
• Homozygous familial hypercholesterolaemia
Interventions Evolocumab compared with placebo
Outcomes Percentage change from baseline in low-density lipoprotein cholesterol levels
Starting date February 2015
Contact information
Notes Amgen
NCT02833844
Trial name or title A Double Blind, Randomized, Placebo Controlled, Multicenter Study to Evaluate Safety, Tolerability, and
Efficacy on LDL-C of Evolocumab (AMG 145) in Subjects With HIV and With Hyperlipidemia and/or
Mixed Dyslipidemia
Methods Parallel randomised controlled trials
Participants Human immunodeficiency virus (HIV)-positive individuals with hyperlipidaemia or mixed dyslipidaemia
(time frame: week 24)
Interventions Evolocumab compared with placebo
Outcomes Percent change from baseline in low-density lipoprotein cholesterol (LDL-C)
Starting date June 2016
Contact information
Notes Amgen
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ODYSSEY DM-Dyslipidemia
Trial name or title ODYSSEY DM-Dyslipidemia
Methods Open-label parallel randomised controlled trials
Participants Inclusion criteria
• Patients with type 2 diabetes and mixed dyslipidaemia whose non-high-density lipoprotein cholesterol
(non-HDL-C) is not adequately controlled with a stable, maximum dose/regimen of statin that is tolerated
by the patient
• 18 years of age or older
• Documented history of atherosclerotic cardiovascular disease (ASCVD) or at least 1 additional
cardiovascular risk factor
• Non-HDL-C ≥ 100 mg/dL
• Triglycerides ≥ 150 mg/dL and < 500 mg/dL
• Stable antihyperglycaemic agents for ≥ 3 months
• No change in weight ≥ 5 kg within the prior 3 months
• On stable dose of medications that are known to influence weight and/or lipids within the previous 3
months
Exclusion criteria
• Use of any lipid-modifying therapies other than statins within the previous 4 weeks (e.g. ezetimibe,
fenofibrate, nicotinic acid, omega-3 fatty acids) or use of over-the-counter products/nutraceuticals known to
impact lipids (e.g. red yeast rice) within previous 4 weeks
• Currently drinking more than 2 standard alcoholic drinks per day
• Body mass index (BMI) > 45 kg/m² or currently enrolled in a weight loss programme and still in active
phase of weight loss
• Glycosylated haemoglobin (HbA1c) ≥ 9%
The above information is not intended to contain all considerations relevant to a patient’s potential partici-
pation in a clinical trial
Interventions • Experimental: Alirocumab will be injected subcutaneously every 2 weeks starting with dose 1, with
potential blinded uptitration to dose 2 at week 12. Background therapy such as antihyperglycaemic agents
and statins will be administered as applicable or as per Investigator’s judgement. Placebo injection for
training purposes will be administered to participants Interventions: drug: ALIROCUMAB SAR236553
(REGN727)
Drug: placebo
Drug: statins
• Active comparator: Usual care will be administered orally on the basis of selection of the investigator
before randomisation and includes initiation of ezetimibe, fenofibrate, nicotinic acid or omega-3 fatty acids.
Alternatively, if randomised to the usual care arm, the investigator may select no additional lipid-lowering
agents. Background therapy such as antihyperglycaemic agents and statins will be administered as applicable
or as per Investigator’s judgement. Placebo injection for training purposes will be administered to
participantsI
Interventions: drug: placebo
Drug: statins
Drug: ezetimibe
Drug: fenofibrate
Drug: nicotinic acid
Drug: omega-3 fatty acids
Outcomes Percent change in non-HDL-C in the intent-to-treat (ITT) population
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ODYSSEY DM-Dyslipidemia (Continued)
Starting date December 2015
Contact information
Notes Sanofi
ODYSSEY Outcomes
Trial name or title ODYSSEY Outcomes
Methods Parallel randomised controlled trials
Participants Inclusion criteria
• Recent (< 52 weeks) hospitalisation for ACS
Exclusion criteria
• Age < 40 years
• ACS event occurring more than 52 weeks before randomisation visit
• LDL-C likely to be <70 mg/dL (< 1.81 mmol/L) with evidence-based medical and dietary
management of dyslipidaemia
The above information is not intended to contain all considerations relevant to a patient’s potential partici-
pation in a clinical trial
Interventions Alirocumab compared with placebo
Outcomes Time from randomisation to first occurrence of one of the following clinical events: CHD death, any non-
fatal MI, fatal and non-fatal ischaemic stroke, unstable angina requiring hospitalisation
Starting date August 2012
Contact information
Notes Sanofi
TAUSSIG
Trial name or title TAUSSIG
Methods Open-label parallel randomised controlled trial
Participants Inclusion criteria
• Participated in a qualifying evolocumab (AMG145) parent protocol OR
• Have a diagnosis of familial hypercholesterolaemia AND
• Males and females ≥ 12 to ≤ 80 years of age
• Stable low-fat diet and lipid-lowering therapies for ≥ 4 weeks
• Low-density lipoprotein cholesterol (LDL-C) ≥ 130 mg/dL (3.4 mmol/L) for people without
diagnosed CHD/CHD risk equivalent OR LDL-C ≥ 100 mg/dL (2.6 mmol/L) for those with diagnosed
CHD or CHD risk equivalent OR people given apheresis with no LDL-C entry requirement
• Fasting triglycerides < 400 mg/dL (4.5 mmol/L)
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TAUSSIG (Continued)
• Body weight ≥ 40 kg at screening for those younger than 18 years
Exclusion criteria
• New York Heart Association (NYHA) class III or IV or last known left ventricular ejection fraction <
30%
• Myocardial infarction, unstable angina, percutaneous coronary intervention (PCI), coronary artery
bypass graft (CABG) or stroke within 3 months of screening
• Planned cardiac surgery or revascularisation
• Uncontrolled cardiac arrhythmia
• Uncontrolled hypertension
Interventions 1 monthly dose of evolocumab compared with 2 monthly dosages of evolocumab
Outcomes Incidence of treatment-emergent adverse events
Starting date June 2015
Contact information
Notes Amgen
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D A T A A N D A N A L Y S E S
This review has no analyses.
A D D I T I O N A L T A B L E S
Table 1. Summary results - clinical events analyses as odds ratios
Number
of
studies
Number of
events
in the
PCSK9 arm
Number of
participants
in the
PCSK9 arm
Number of
events
in the
comparison
arm
Number of
participants
in the
comparison
arm
Fixed-effect
(95% CI)
Between-
study
heterogeneity
P value
Placebo comparison Placebo comparison
All-causemor-
tality
12 580 31358 558 29326 1.02 (0.91 to
1.14)
0.159
Any cardiovas-
cular event
8 1790 30355 2009 28939 0.86 (0.80 to
0.92)
0.803
Any myocar-
dial infarction
10 686 30610 869 29038 0.77 (0.69 to
0.85)
0.674
Any stroke 8 265 29828 340 28672 0.76 (0.65 to
0.89)
0.185
Any adverse
event
13 22593 31611 20435 29427 1.08 (1.04 to
1.12)
0.38
Myalgia 12 1249 31428 1094 29363 1.07 (0.99 to
1.16)
0.873
Influenza 6 191 2923 82 1477 1.19 (0.91 to
1.55)
1
Hypertension 8 110 3436 60 1593 0.86 (0.62 to
1.18)
0.741
Cancer 5 83 2851 46 1442 0.91 (0.63 to
1.31)
0.964
Type 2 dia-
betes
7 956 17535 911 16681 1.04 (0.95 to
1.14)
0.983
Elevated crea-
tinine
8 319 30399 309 28933 0.85 (0.73 to
0.99)
0.419
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Table 1. Summary results - clinical events analyses as odds ratios (Continued)
Neurological
events
5 289 16036 242 14919 1.04 (0.88 to
1.24)
0.759
Ezetimibe and statin comparison Ezetimibe and statin
ison
All-causemor-
tality
Any cardiovas-
cular event
3 29 3079 33 1691 0.45 (0.27 to
0.75)
0.712
Any myocar-
dial infarction
Any stroke
Any adverse
event
5 2290 3309 1347 2067 1.18 (1.05 to
1.34)
0.478
Myalgia 5 127 3309 81 2067 1.09 (0.81 to
1.48)
0.715
Influenza 4 113 3183 51 1942 1.28 (0.91 to
1.80)
0.45
Hypertension 3 6 207 12 453 1.10 (0.41 to
2.96)
0.893
Cancer
Type 2 dia-
betes
4 35 3183 22 1942 1.10 (0.63 to
1.93)
0.057
Elevated crea-
tinine
5 20 3183 29 1942 0.51 (0.28 to
0.92)
0.969
Neurological
events
2 5 207 9 453 1.22 (0.40 to
3.69)
1
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Table 2. Summary results - clinical events analyses as risk differences
Number
of
studies
Number of
events
in the
PCSK9 arm
Number of
participants
in the
PCSK9 arm
Number of
events
in the
comparison
arm
Number of
participants
in the
comparison
arm
Fixed-effect
(95% CI)
Between-
study
heterogeneity
P value
Placebo comparison Placebo comparison
All-causemor-
tality
12 580 31358 558 29326 0.000 (-0.002
to 0.002)
0.781
Any cardiovas-
cular event
8 1790 30355 2009 28939 -0.009 (-0.
013 to -0.005)
0.005
Any myocar-
dial infarction
10 686 30610 869 29038 -0.007 (-0.
009 to -0.004)
< 0.001
Any stroke 8 265 29828 340 28672 -0.003 (-0.
004 to -0.001)
0.409
Any adverse
event
13 22593 31611 20435 29427 0.015 (0.008
to 0.023)
< 0.001
Myalgia 12 1249 31428 1094 29363 0.002 (-0.001
to 0.006)
0.979
Influenza 6 191 2923 82 1477 0.010 (-0.005
to 0.025)
0.513
Hypertension 8 110 3436 60 1593 -0.005 (-0.
016 to 0.006)
1
Cancer 5 83 2851 46 1442 -0.003 (-0.
013 to 0.008)
0.892
Type 2 dia-
betes
7 956 17535 911 16681 0.002 (-0.03
to 0.07)
0.73
Elevated crea-
tinine
8 319 30399 309 28933 -0.002 (-0.
003 to -0.000)
< 0.001
Neurological
events
5 289 16036 242 14919 0.001 (-0.002
to 0.004)
0.923
Ezetimibe and statin comparison Ezetimibe and statin
ison
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Table 2. Summary results - clinical events analyses as risk differences (Continued)
All-causemor-
tality
Any cardiovas-
cular event
3 29 3079 33 1691 -0.011 (-0.
017 to -0.004)
1
Any myocar-
dial infarction
Any stroke
Any adverse
event
5 2290 3309 1347 2067 0.037 (0.011
to 0.063)
0.862
Myalgia 5 127 3309 81 2067 0.003 (-0.007
to 0.014)
0.901
Influenza 4 113 3183 51 1942 0.009 (-0.002
to 0.019)
1
Hypertension 3 6 207 12 453 0.002 (-0.020
to 0.025)
0.922
Cancer
Type 2 dia-
betes
4 35 3183 22 1942 0.001 (-0.007
to 0.008)
0.027
Elevated crea-
tinine
5 20 3183 29 1942 -0.006 (-0.
012 to -0.000)
0.984
Neurological
events
2 5 207 9 453 0.004 (-0.019
to 0.028)
1
Table 3. Summary results - biomarker analyses at 6 months
Number of
studies
Number of
PCSK9
participants
Number of
comparator
arm
participants
Fixed-effect
(95% CI)
Random-effects
(95% CI)
Between-study
heterogeneity
P value
Placebo comparison Placebo comparison
LDL-C %
change
8 3255 1527 -57.62 (-59.37
to -55.87)
-53.86 (-58.64
to -49.08)
< 0.001
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Table 3. Summary results - biomarker analyses at 6 months (Continued)
HDL-C %
change
5 2324 1175 5.48 (4.37 to 6.
59)
6.00 (4.31 to 7.
69)
0.19
Triglycerides %
change
5 2324 1175 -14.62 (-16.74
to -12.50)
-11.39 (-17.04
to -5.74)
< 0.001
Total cholesterol
% change
2 1762 895 -35.79 (-37.36
to -34.23)
-31.41 (-43.65
to -19.16)
< 0.001
Apolipoprotein
A1 % change
3 2043 1033 3.49 (2.38 to 4.
60)
3.50 (2.37 to 4.
64)
0.36
Apolipoprotein
B % change
6 2507 1239 -47.79 (-49.51
to -46.08)
-41.93 (-49.76
to -34.10)
< 0.001
Lipoprotein(a)
% change
4 2252 1140 -22.43 (-24.30
to -20.56)
-19.80 (-25.43
to -14.17)
< 0.001
Non-HDL-C %
change
4 2252 1140 -50.03 (-51.73
to -48.33)
-47.17 (-53.92
to -40.42)
< 0.001
HbA1c absolute
change
2 490 245 0.00 (-0.04 to 0.
05)
0.01 (-0.06 to 0.
08)
0.151
Ezetimibe and statin comparison Ezetimibe and statin
LDL-C %
change
5 3309 2067 -52.17 (-53.91
to -50.43)
-39.20 (-56.15
to -22.26)
< 0.001
HDL-C %
change
3 333 578 7.53 (5.54 to 9.
51)
6.42 (1.31 to 11.
52)
0.002
Triglycerides %
change
2 229 327 -3.47 (-8.26 to 1.
32)
-3.47 (-8.26 to 1.
32)
0.46
Total cholesterol
% change
Apolipoprotein
A1 % change
Apolipoprotein
B % change
3 333 578 -26.86 (-29.50
to -24.22)
-26.72 (-30.26
to -23.19)
0.169
Lipoprotein(a)
% change
2 207 453 -19.51 (-24.48
to -14.53)
-19.51 (-24.48
to -14.53)
0.60
77PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 3. Summary results - biomarker analyses at 6 months (Continued)
Non-HDL-C %
change
2 207 453 -28.19 (-32.79
to -23.59)
-28.19 (-32.79
to -23.59)
0.65
HbA1c absolute
change
Ezetimibe comparison Ezetimibe comparison
LDL-C %
change
2 531 292 -30.20 (-34.18
to -26.23)
-30.20 (-34.18
to -26.23)
0.71
HDL-C %
change
2 531 292 7.40 (5.11 to 9.
70)
7.01 (3.70 to 10.
32)
0.22
Triglycerides %
change
2 531 292 -0.43 (-4.90 to 4.
03)
-0.43 (-4.90 to 4.
03)
0.89
Total cholesterol
% change
2 531 292 -15.51 (-18.18
to -12.83)
-15.84 (-19.37
to -12.30)
0.24
Apolipoprotein
A1 % change
2 531 292 6.13 (4.34 to 7.
91)
6.13 (4.34 to 7.
91)
0.68
Apolipoprotein
B % change
2 531 292 -23.18 (-26.28
to -20.08)
-23.18 (-26.28
to -20.08)
0.37
Lipoprotein(a)
% change
2 531 292 -18.70 (-23.03
to -14.37)
-13.69 (-30.60
to 3.21)
0.003
Non-HDL-C %
change
2 531 292 -23.45 (-27.07
to -19.83)
-23.45 (-27.07
to -19.83)
0.57
HbA1c absolute
change
Table 4. Summary results - biomarker analyses at 1 year
Number of
studies
Number of
PCSK9
participants
Number of
comparator
arm
participants
Fixed-effect
(95% CI)
Random-effects
(95% CI)
Between-study
heterogeneity
P value
Placebo comparison Placebo comparison
LDL-C %
change
6 29865 28694 -52.80 (-53.46
to 52.14)
-52.87 (-60.03
to -45.72)
< 0.001
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Table 4. Summary results - biomarker analyses at 1 year (Continued)
HDL-C %
change
4 14528 14127 5.55 (5.07 to 6.
03)
6.06 (4.30 to 7.
82)
0.102
Triglycerides %
change
3 14319 14020 -12.53 (-15.45
to -9.61)
-12.53 (-15.45
to -9.61)
0.679
Total cholesterol
% change
2 808 409 -31.33 (-33.80
to -28.86)
-28.47 (-38.85
to -18.10)
< 0.001
Apolipoprotein
A1 % change
1 599 302 3.00 (1.31 to 4.
69)
Apolipoprotein
B % change
4 14528 14127 -47.18 (-48.29
to -48.29)
-43.51 (-48.88
to -38.13)
< 0.001
Lipoprotein(a)
% change
Non-HDL-C %
change
2 808 409 -47.16 (-50.77
to -43.55)
-43.46 (-57.45
to -29.47)
0.001
Glu-
cose (mg/dL) ab-
solute change*
2 13720 13718 1.80 (0.61 to 2.
99)
HbA1c absolute
change*
2 13720 13718 0.02 (-0.01 to 0.
05)
Ezetimibe and statin comparison Ezetimibe and statin
LDL-C %
change
1 2976 1489 -58.40 (-60.40
to -56.40)
HDL-C %
change
1 736 368 5.40 (3.09 to 7.
71)
Triglycerides %
change
1 736 368 -10.00 (-13.59
to -6.41)
Total cholesterol
% change
Apolipoprotein
A1 % change
1 736 368 4.30 (2.61 to 5.
99)
Apolipoprotein
B % change
1 736 368 -38.80 (-41.18
to -36.42)
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Table 4. Summary results - biomarker analyses at 1 year (Continued)
Lipoprotein(a)
% change
1 736 368 -20.80 (-23.95
to -17.65)
Non-HDL-C %
change
1 736 368 -44.00 (-46.77
to -41.23)
Glu-
cose (mg/dL) ab-
solute change*
HbA1c absolute
change
*On the basis of the combined analysis of SPIRE-1 and SPIRE-2, study-specific estimates were unavailable, hence no random-effects
or between-study heterogeneity estimates could be calculated
A P P E N D I C E S
Appendix 1. Search strategies
MEDLINE search strategy
1. exp antibodies, monoclonal/
2. monoclonal antibod*.tw.
3. MAB*.tw.
4. evolocumab.tw.
5. amg 145.tw.
6. amg145.tw.
7. alirocumab.tw.
8. regn 727.tw.
9. regn727.tw.
10. sar 236553.tw.
11. sar236553.tw.
12. 1D05-IgG2.tw.
13. LGT209.tw.
14. RG7652.tw.
15. Bococizumab.tw.
16. “pf 04950615”.tw.
17. pf04950615.tw.
18. rn 316.tw.
19. rn316.tw.
20. or/1-19
21. exp Proprotein Convertases/
22. proprotein convertase*.tw.
23. pro-protein convertase*.tw.
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24. pcsk9.tw.
25. serine proteinase*.tw.
26. or/21-25
27. exp Cardiovascular Diseases/
28. cardio*.tw.
29. cardia*.tw.
30. heart*.tw.
31. coronary*.tw.
32. angina*.tw.
33. ventric*.tw.
34. myocard*.tw.
35. pericard*.tw.
36. isch?em*.tw.
37. emboli*.tw.
38. arrhythmi*.tw.
39. thrombo*.tw.
40. atrial fibrillat*.tw.
41. tachycardi*.tw.
42. endocardi*.tw.
43. (sick adj sinus).tw.
44. exp Stroke/
45. (stroke or stokes).tw.
46. cerebrovasc*.tw.
47. cerebral vascular.tw.
48. apoplexy.tw.
49. (brain adj2 accident*).tw.
50. ((brain* or cerebral or lacunar) adj2 infarct*).tw.
51. exp Hyperlipidemias/
52. hyperlipid*.tw.
53. hyperlip?emia*.tw.
54. hypercholesterol*.tw.
55. hypercholester?emia*.tw.
56. hyperlipoprotein?emia*.tw.
57. hypertriglycerid?emia*.tw.
58. exp Arteriosclerosis/
59. exp Cholesterol/
60. cholesterol.tw.
61. “coronary risk factor* ”.tw.
62. exp Cognition/
63. exp dementia/
64. cognitive function*.tw.
65. dementia.tw.
66. alzheimer*.tw.
67. or/27-66
68. 20 and 26 and 67
69. randomized controlled trial.pt.
70. controlled clinical trial.pt.
71. randomized.ab.
72. placebo.ab.
73. drug therapy.fs.
74. randomly.ab.
75. trial.ab.
76. groups.ab.
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77. 69 or 70 or 71 or 72 or 73 or 74 or 75 or 76
78. exp animals/ not humans.sh.
79. 77 not 78
80. 68 and 79
81. limit 80 to yr=“2005 -Current”
CENTRAL search strategy
#1 MeSH descriptor: [Antibodies, Monoclonal] explode all trees
#2 monoclonal next antibod*
#3 MAB*
#4 evolocumab
#5 “amg 145” or amg145
#6 alirocumab
#7 “regn 727” or regn727 or “sar 236553” or sar236553 or 1D05-IgG2 or LGT209 or RG7652
#8 Bococizumab
#9 “pf 04950615” or pf04950615 or “rn 316” or rn316
#10 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9
#11 MeSH descriptor: [Proprotein Convertases] explode all trees
#12 proprotein next convertase*
#13 pro-protein next convertase*
#14 pcsk9
#15 serine next proteinase*
#16 #11 or #12 or #13 or #14 or #15
#17 MeSH descriptor: [Cardiovascular Diseases] explode all trees
#18 cardio*
#19 cardia*
#20 heart*
#21 coronary*
#22 angina*
#23 ventric*
#24 myocard*
#25 pericard*
#26 isch?em*
#27 emboli*
#28 arrhythmi*
#29 thrombo*
#30 atrial next fibrillat*
#31 tachycardi*
#32 endocardi*
#33 (sick next sinus)
#34 MeSH descriptor: [Stroke] explode all trees
#35 (stroke or stokes)
#36 cerebrovasc*
#37 cerebral next vascular
#38 apoplexy
#39 (brain near/2 accident*)
#40 ((brain* or cerebral or lacunar) near/2 infarct*)
#41 MeSH descriptor: [Hyperlipidemias] explode all trees
#42 hyperlipid*
#43 hyperlip?emia*
#44 hypercholesterol*
#45 hypercholester?emia*
#46 hyperlipoprotein?emia*
#47 hypertriglycerid?emia*
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#48 MeSH descriptor: [Arteriosclerosis] explode all trees
#49 MeSH descriptor: [Cholesterol] explode all trees
#50 cholesterol
#51 “coronary risk factor*”
#52 MeSH descriptor: [Cognition] explode all trees
#53 MeSH descriptor: [Dementia] explode all trees
#54 cognitive next function*
#55 dementia
#56 alzheimer*
#57 #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34
or #35 or #36 or #37 or #38 or #39 or #40 or #41 or #42 or #43 or #44 or #45 or #46 or #47 or #48 or #49 or #50 or #51 or #52 or
#53 or #54 or #55 or #56
#58 #10 and #16 and #57 Publication Year from 2005 to 2014
Embase search strategy
1. exp monoclonal antibody/
2. monoclonal antibod*.tw.
3. MAB*.tw.
4. evolocumab.tw.
5. amg 145.tw.
6. amg145.tw.
7. alirocumab.tw.
8. regn 727.tw.
9. regn727.tw.
10. sar 236553.tw.
11. sar236553.tw.
12. 1D05-IgG2.tw.
13. LGT209.tw.
14. RG7652.tw.
15. Bococizumab.tw.
16. “pf 04950615”.tw.
17. pf04950615.tw.
18. rn 316.tw.
19. rn316.tw.
20. or/1-19
21. exp serine proteinase/
22. proprotein convertase*.tw.
23. pro-protein convertase*.tw.
24. serine proteinase*.tw.
25. pcsk9.tw.
26. or/21-25
27. exp cardiovascular disease/
28. cardio*.tw.
29. cardia*.tw.
30. heart*.tw.
31. coronary*.tw.
32. angina*.tw.
33. ventric*.tw.
34. myocard*.tw.
35. pericard*.tw.
36. isch?em*.tw.
37. emboli*.tw.
38. arrhythmi*.tw.
39. thrombo*.tw.
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40. atrial fibrillat*.tw.
41. tachycardi*.tw.
42. endocardi*.tw.
43. (sick adj sinus).tw.
44. exp cerebrovascular disease/
45. (stroke or stokes).tw.
46. cerebrovasc*.tw.
47. cerebral vascular.tw.
48. apoplexy.tw.
49. (brain adj2 accident*).tw.
50. ((brain* or cerebral or lacunar) adj2 infarct*).tw.
51. exp hyperlipidemia/
52. hyperlipid*.tw.
53. hyperlip?emia*.tw.
54. hypercholesterol*.tw.
55. hypercholester?emia*.tw.
56. hyperlipoprotein?emia*.tw.
57. hypertriglycerid?emia*.tw.
58. exp Arteriosclerosis/
59. exp Cholesterol/
60. cholesterol.tw.
61. “coronary risk factor*”.tw.
62. exp cognition/
63. exp dementia/
64. cognitive function*.tw.
65. dementia.tw.
66. alzheimer*.tw.
67. or/27-66
68. 20 and 26 and 67
69. random$.tw.
70. factorial$.tw.
71. crossover$.tw.
72. cross over$.tw.
73. cross-over$.tw.
74. placebo$.tw.
75. (doubl$ adj blind$).tw.
76. (singl$ adj blind$).tw.
77. assign$.tw.
78. allocat$.tw.
79. volunteer$.tw.
80. crossover procedure/
81. double blind procedure/
82. randomized controlled trial/
83. single blind procedure/
84. 69 or 70 or 71 or 72 or 73 or 74 or 75 or 76 or 77 or 78 or 79 or 80 or 81 or 82 or 83
85. (animal/ or nonhuman/) not human/
86. 84 not 85
87. 68 and 86
88. limit 87 to embase
89. limit 88 to yr=“2005 -Current”
Web of Science search strategy
# 12 #11 AND #10
# 11 TS=((random* or blind* or allocat* or assign* or trial* or placebo* or crossover* or cross-over*))
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# 10 #9 AND #8 AND #7
# 9 TS=(“proprotein convertase*” or “pro-protein convertase*” or pcsk9 or “serine proteinase*”)
# 8 TS=(“monoclonal antibod*” or MAB* or evolocumab or “amg 145” or amg145 or alirocumab or “regn 727” or regn727 or “sar
236553” or sar236553 or 1D05-IgG2 or LGT209 or RG7652 or Bococizumab or “pf 04950615” or pf04950615 or “rn 316” or
rn316)
# 7 #6 OR #5 OR #4 OR #3 OR #2 OR #1
# 6 TS=(“cognitive function*” or dementia or alzheimer*)
# 5 TS=(cardio* OR cardia* OR heart* OR coronary* OR angina* OR ventric* OR myocard*)
# 4 TS=(pericard* OR isch?em* OR emboli* OR arrhythmi* OR thrombo*)
# 3 TS=(“atrial fibrillat*” OR tachycardi* OR endocardi*)
# 2 TS=(stroke OR stokes OR cerebrovasc* OR cerebral OR apoplexy OR (brain SAME accident*) OR (brain SAME infarct*))
# 1 TS=(hyperlipid* OR hyperlip?emia*OR hypercholesterol*OR hypercholester?emia*OR hyperlipoprotein?emia*OR hypertriglyc-
erid?emia*)
Appendix 2. Biomarker forest plots
Figure 16; Figure 17; Figure 18; Figure 19; Figure 20; Figure 21; Figure 22; Figure 23; Figure 24; Figure 25; Figure 26; Figure 27;
Figure 28; Figure 29; Figure 30; Figure 31; Figure 32; Figure 33; Figure 34; Figure 35; Figure 36; Figure 37; Figure 38; Figure 39;
Figure 40; Figure 41; Figure 42; Figure 43; Figure 44; Figure 45; Figure 46; Figure 47; Figure 48; Figure 49
Figure 16. Association of PCSK9 inhibitors compared with placebo with mean percentage change from
baseline in HDL-C at six months.
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Figure 17. Association of PCSK9 inhibitors compared with placebo with mean percentage change from
baseline in triglycerides at six months.
Figure 18. Association of PCSK9 inhibitors compared with placebo with mean percentage change from
baseline in total cholesterol at six months.
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Figure 19. Association of PCSK9 inhibitors compared with placebo with mean percentage change from
baseline in apolipoprotein A1 at six months.
Figure 20. Association of PCSK9 inhibitors compared with placebo with mean percentage change from
baseline in apolipoprotein B at six months.
87PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 21. Association of PCSK9 inhibitors compared with placebo with mean percentage change from
baseline in lipoprotein(a) at six months.
Figure 22. Association of PCSK9 inhibitors compared with placebo with mean percentage change from
baseline in non-HDL-C at six months.
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Figure 23. Association of PCSK9 inhibitors compared with placebo with mean absolute change from
baseline in HbA1c at six months.
Figure 24. Association of PCSK9 inhibitors compared with ezetimibe and statins with mean percentage
change from baseline in HDL-C at six months.
89PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 25. Association of PCSK9 inhibitors compared with ezetimibe and statins with mean percentage
change from baseline in triglycerides at six months.
Figure 26. Association of PCSK9 inhibitors compared with ezetimibe and statins with mean percentage
change from baseline in apolipoprotein B at six months.
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Figure 27. Association of PCSK9 inhibitors compared with ezetimibe and statins with mean percentage
change from baseline in lipoprotein(a) at six months.
Figure 28. Association of PCSK9 inhibitors compared with ezetimibe and statins with mean percentage
change from baseline in non-HDL-C at six months.
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Figure 29. Association of PCSK9 inhibitors compared with ezetimibe with mean percentage change from
baseline in HDL-C at six months.
Figure 30. Association of PCSK9 inhibitors compared with ezetimibe with mean percentage change from
baseline in triglycerides at six months.
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Figure 31. Association of PCSK9 inhibitors compared with ezetimibe with mean percentage change from
baseline in total cholesterol at six months.
Figure 32. Association of PCSK9 inhibitors compared with ezetimibe with mean percentage change from
baseline in apolipoprotein A1 at six months.
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Figure 33. Association of PCSK9 inhibitors compared with ezetimibe with mean percentage change from
baseline in apolipoprotein B at six months.
Figure 34. Association of PCSK9 inhibitors compared with ezetimibe with mean percentage change from
baseline in lipoprotein(a) at six months.
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Figure 35. Association of PCSK9 inhibitors compared with ezetimibe with mean percentage change from
baseline in non-HDL-C at six months.
Figure 36. Association of PCSK9 inhibitors compared with placebo with mean percentage change from
baseline in LDL-C at 12 months.
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Figure 37. Association of PCSK9 inhibitors compared with placebo with mean percentage change from
baseline in HDL-C at 12 months.
Figure 38. Association of PCSK9 inhibitors compared with placebo with mean percentage change from
baseline in triglycerides at 12 months.
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Figure 39. Association of PCSK9 inhibitors compared with placebo with mean percentage change from
baseline in total cholesterol at 12 months.
Figure 40. Association of PCSK9 inhibitors compared with placebo with mean percentage change from
baseline in apolipoprotein A1 at 12 months.
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Figure 41. Association of PCSK9 inhibitors compared with placebo with mean percentage change from
baseline in apolipoprotein B at 12 months.
Figure 42. Association of PCSK9 inhibitors compared with placebo with mean percentage change from
baseline in non-HDL-C at 12 months.
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Figure 43. Association of PCSK9 inhibitors compared with ezetimibe and statins with mean percentage
change from baseline in LDL-C at 12 months.
Figure 44. Association of PCSK9 inhibitors compared with ezetimibe and statins with mean percentage
change from baseline in HDL-C at 12 months.
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Figure 45. Association of PCSK9 inhibitors compared with ezetimibe and statins with mean percentage
change from baseline in triglycerides at 12 months.
Figure 46. Association of PCSK9 inhibitors compared with ezetimibe and statins with mean percentage
change from baseline in apolipoprotein A1 at 12 months.
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Figure 47. Association of PCSK9 inhibitors compared with ezetimibe and statins with mean percentage
change from baseline in apolipoprotein B at 12 months.
Figure 48. Association of PCSK9 inhibitors compared with ezetimibe and statins with mean percentage
change from baseline in lipoprotein(a) at 12 months.
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Figure 49. Association of PCSK9 inhibitors compared with ezetimibe and statins with mean percentage
change from baseline in non-HDL-C at 12 months.
Appendix 3. Clinical endpoint forest plots
Figure 50; Figure 51; Figure 52; Figure 53; Figure 54; Figure 55; Figure 56; Figure 57; Figure 58; Figure 59; Figure 60; Figure 61;
Figure 62; Figure 63; Figure 64; Figure 65
Figure 50. Association of PCSK9 inhibitors compared with placebo with the incidence of all-cause mortality.
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Figure 51. Association of PCSK9 inhibitors compared with placebo with the incidence of any MI.
Figure 52. Association of PCSK9 inhibitors compared with placebo with the incidence of any stroke.
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Figure 53. Association of PCSK9 inhibitors compared with placebo with the incidence of myalgia.
Figure 54. Association of PCSK9 inhibitors compared with placebo with the incidence of influenza.
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Figure 55. Association of PCSK9 inhibitors compared with placebo with the incidence of hypertension.
Figure 56. Association of PCSK9 inhibitors compared with placebo with the incidence of any cancer
diagnosis.
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Figure 57. Association of PCSK9 inhibitors compared with placebo with the incidence of type 2 diabetes.
Figure 58. Association of PCSK9 inhibitors compared with placebo with the incidence of elevated creatine.
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Figure 59. Association of PCSK9 inhibitors compared with placebo with the incidence of neurological
events.
Figure 60. Association of PCSK9 inhibitors compared with ezetimibe and statins with the incidence of
myalgia.
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Figure 61. Association of PCSK9 inhibitors compared with ezetimibe and statins with the incidence of
influenza.
Figure 62. Association of PCSK9 inhibitors compared with ezetimibe and statins with the incidence of
hypertension.
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Figure 63. Association of PCSK9 inhibitors compared with ezetimibe and statins with the incidence of type
2 diabetes.
Figure 64. Association of PCSK9 inhibitors compared with ezetimibe and statins with the incidence of
elevated creatinine.
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Figure 65. Association of PCSK9 inhibitors compared with ezetimibe and statins with the incidence
neurological events
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We note the following deviations from the protocol.
• We intended to present a ’Risk of bias’ figure depicting risk of bias per item, weighted for how much an individual RCT
contributed to the overall effect estimate of PCSK9 inhibitors on LDL-C. However, some studies did not report on LDL-C at all, or
did not report it at the same time point, making it impossible to present such a figure.
• Owing to the small number of events off all-cause mortality and the CVD endpoints, we decided against using the usual inverse
variance method of pooling, which may result in biased estimates. Instead, we pooled clinical events by reconstructing individual
participant data based on cell frequencies, and analysed these data using a mixed-effect generalised linear regression model (Bradburn
2007; Sweeting 2004) with a random intercept (fixed-effect).
• We meta-analysed biomarker results despite considerable heterogeneity in continuous endpoints, this contrary to the protocol
statement that no meta-analysis would be performed if heterogeneity would be larger than 50%. We decided to combine results
because estimates were universally on one side of the neutral effect.
• Owing to the small number of events, we performed all subgroup analyses for LDL-C instead of CVD. Similarly, subgroups
explored were slightly different from those described in the protocol as the result of available data.
• We intended to extract data for continuous endpoints as mean percentage change from baseline, or as the difference at the end of
follow-up. However, the latter was unavailable in most studies, and we focused on the former.
• Instead of data on cognitive function, we decided (post hoc) to extract data on neurological events.
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